UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2021~~2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-35006

SPECTRUM PHARMACEUTICALS, ~~INC~~INC.

(Exact name of registrant as specified in its charter)


Delaware						93-0979187
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

~~11500 South Eastern Avenue~~Pilot House - Lewis Wharf, 2 Atlantic Ave

~~Suite 220~~6th Floor

~~Henderson~~Boston

~~Nevada~~MA

~~89052~~02110

(Address of principal executive offices)

(Zip Code)

~~(702) 835-6300~~

(Registrant’s telephone number, including area code): (617) 586-3900

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SPPI	The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November ~~8, 2021, 163,956,341~~ 7, 2022, 203,205,510shares of the registrant’s common stock were outstanding.

Table of Contents

Spectrum Pharmaceuticals, Inc.

Quarterly Report on Form 10-Q

For the Three and Nine Months Ended September 30, ~~2021~~2022

TABLE OF CONTENTS


Item		Page
	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Loss	5
	Condensed Consolidated Statements of Stockholders’ Equity	6
	Condensed Consolidated Statements of Cash Flows	8
	Notes to Condensed Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	33

	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	3334
Item 1A.	Risk Factors	34
Item 2.	~~Unregistered Sales of Equity Securities and Use of Proceeds~~	36
~~Item 3.~~	~~Defaults Upon Senior Securities~~	37
~~Item 4.~~	~~Mine Safety Disclosures~~	37
~~Item 5.~~	~~Other Information~~	37
~~Item~~ 6.	Exhibits	3836
	Signatures	3937

.Items 2 through 5 of Part II have been omitted because they are not applicable with respect to the current reporting period.

SPECTRUM PHARMACEUTICALS, INC. ~~®, and ROLONTIS® are~~® is a registered ~~trademarks~~trademark of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™, ROLVEDON™ and the Spectrum Pharmaceuticals’ logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Table of Contents

Part I: Financial Information

Item 1: Financial Statements

SPECTRUM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and par value amounts)

(Unaudited)


		September 30, 2021		December 31, 2020			September 30, 2022		December 31, 2021
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	107,435	$	46,009	Cash and cash equivalents	$	56,255	$	88,539
Marketable securities	Marketable securities	26,160		134,016		Marketable securities	43,997		12,108
Accounts receivable, net		—		67
Other receivables	Other receivables	3,863		2,394		Other receivables	586		1,028

Inventories						Inventories	9,373		—
Prepaid expenses and other current assets	Prepaid expenses and other current assets	2,540		4,161		Prepaid expenses and other current assets	2,769		2,277

Total current assets	Total current assets	139,998		186,647		Total current assets	112,980		103,952
Property and equipment, net	Property and equipment, net	507		3,577		Property and equipment, net	422		455

Facility and equipment under lease	Facility and equipment under lease	2,881		2,247		Facility and equipment under lease	1,869		2,505
Other assets	Other assets	4,415		4,327		Other assets	3,658		4,636
Total assets	Total assets	$	147,801	$	196,798	Total assets	$	118,929	$	111,548
LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable and other accrued liabilities	Accounts payable and other accrued liabilities	$	48,982	$	43,771	Accounts payable and other accrued liabilities	$	42,011	$	41,258
Accrued payroll and benefits	Accrued payroll and benefits	8,290		9,375		Accrued payroll and benefits	7,613		11,971

Total current liabilities	Total current liabilities	57,272		53,146		Total current liabilities	49,624		53,229

Loan payable, long-term						Loan payable, long-term	28,488		—
Other long-term liabilities	Other long-term liabilities	11,065		9,409		Other long-term liabilities	4,965		10,766
Total liabilities	Total liabilities	68,337		62,555		Total liabilities	83,077		63,995
Commitments and contingencies (Note 6)		0		0
Commitments and contingencies (Note 7)						Commitments and contingencies (Note 7)
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	—		—		Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	—		—
Common stock, $0.001 par value; 300,000,000 shares authorized; 163,957,900 and 146,083,110 issued and outstanding at September 30, 2021 and December 31, 2020, respectively		164		146
Common stock, $0.001 par value; 300,000,000 shares authorized; 203,339,656 and 164,502,013 issued and outstanding at September 30, 2022 and December 31, 2021, respectively						Common stock, $0.001 par value; 300,000,000 shares authorized; 203,339,656 and 164,502,013 issued and outstanding at September 30, 2022 and December 31, 2021, respectively	203		165
Additional paid-in capital	Additional paid-in capital	1,086,989		1,021,221		Additional paid-in capital	1,148,996		1,094,353
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(3,481)		(1,829)		Accumulated other comprehensive loss	(3,009)		(3,042)
Accumulated deficit	Accumulated deficit	(1,004,208)		(885,295)		Accumulated deficit	(1,110,338)		(1,043,923)
Total stockholders’ equity	Total stockholders’ equity	79,464		134,243		Total stockholders’ equity	35,852		47,553
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	147,801	$	196,798	Total liabilities and stockholders’ equity	$	118,929	$	111,548

See accompanying notes to these unaudited condensed consolidated financial statements.

Table of Contents

SPECTRUM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Operating costs and expenses:
Selling, general and administrative $ 12,243 $ 15,116 $ 41,515 $ 44,654
Research and development 20,850 24,453 69,335 62,192
Total operating costs and expenses 33,093 39,569 110,850 106,846
Loss from continuing operations before other income (expense) and income taxes (33,093) (39,569) (110,850) (106,846)
Other income (expense):
Interest income, net 11 188 121 1,217
Other income (expense), net 9 (9,131) (7,948) (15,720)
Total other income (expense) 20 (8,943) (7,827) (14,503)
Loss from continuing operations before income taxes (33,073) (48,512) (118,677) (121,349)
Provision for income taxes from continuing operations — (6) (9) (15)
Loss from continuing operations (33,073) (48,518) (118,686) (121,364)
Income (loss) from discontinued operations, net of income taxes (11) 66 (227) 255
Net loss $ (33,084) $ (48,452) $ (118,913) $ (121,109)
Basic and diluted loss per share:
Loss from continuing operations $ (0.21) $ (0.37) $ (0.77) $ (1.02)
Income (loss) from discontinued operations $ (0.00) $ 0.00 $ (0.00) $ 0.00
Net loss per share, basic and diluted $ (0.21) $ (0.37) $ (0.78) $ (1.02)
Weighted average shares outstanding, basic and diluted 159,261,818 131,455,727 153,341,854 118,664,914


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021




Operating costs and expenses:


Selling, general and administrative	$	8,263	$	12,243	$	27,518	$	41,515
Research and development	13,335		20,850		33,535		69,335

Total operating costs and expenses	21,598		33,093		61,053		110,850
Loss from continuing operations before other income (expense) and income taxes	(21,598)		(33,093)		(61,053)		(110,850)
Other income (expense):
Interest income, net	128		11		256		121
Other income (expense), net	(443)		9		(5,534)		(7,948)
Total other income (expense)	(315)		20		(5,278)		(7,827)
Loss from continuing operations before income taxes	(21,913)		(33,073)		(66,331)		(118,677)
Provision for income taxes from continuing operations	(16)		—		(45)		(9)
Loss from continuing operations	(21,929)		(33,073)		(66,376)		(118,686)
Income (loss) from discontinued operations, net of income taxes	4		(11)		(39)		(227)
Net loss	$	(21,925)	$	(33,084)	$	(66,415)	$	(118,913)

Basic and diluted loss per share:
Loss from continuing operations	$	(0.12)	$	(0.21)	$	(0.37)	$	(0.77)
Income (loss) from discontinued operations	$	0.00	$	(0.00)	$	(0.00)	$	(0.00)
Net loss per share, basic and diluted	$	(0.12)	$	(0.21)	$	(0.37)	$	(0.78)
Weighted average shares outstanding, basic and diluted	188,358,072		159,261,818		177,818,168		153,341,854

See accompanying notes to these unaudited condensed consolidated financial statements.

Table of Contents

SPECTRUM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net loss	Net loss	$	(33,084)	$	(48,452)	$	(118,913)	$	(121,109)	Net loss	$	(21,925)	$	(33,084)	$	(66,415)	$	(118,913)
Other comprehensive income (loss):	Other comprehensive income (loss):									Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax	Unrealized gain (loss) on available-for-sale securities, net of tax	(1)		73		(1,130)		(61)		Unrealized gain (loss) on available-for-sale securities, net of tax	32		(1)		(14)		(1,130)
Foreign currency translation adjustments	Foreign currency translation adjustments	(153)		457		(522)		835		Foreign currency translation adjustments	(86)		(153)		47		(522)
Other comprehensive income (loss)	Other comprehensive income (loss)	(154)		530		(1,652)		774		Other comprehensive income (loss)	(54)		(154)		33		(1,652)
Total comprehensive loss	Total comprehensive loss	$	(33,238)	$	(47,922)	$	(120,565)	$	(120,335)	Total comprehensive loss	$	(21,979)	$	(33,238)	$	(66,382)	$	(120,565)

See accompanying notes to these unaudited condensed consolidated financial statements.

Table of Contents

SPECTRUM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

(Unaudited)


		Common Stock			Additional Paid-In Capital				Accumulated Other Comprehensive Loss			Accumulated Deficit				Total Stockholders' Equity				Common Stock					Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Stockholders' Equity
		Shares	Amount								Shares								Amount
Balance as of December 31, 2020		146,083,110	$	146			$	1,021,221						$	(1,829)			$	(885,295)		$	134,243
Balance as of December 31, 2021																			Balance as of December 31, 2021	164,502,013			$	165		$	1,094,353		$	(3,042)		$	(1,043,923)		$	47,553
Net loss																			Net loss	—			—		—			—			(15,442)			(15,442)
Other comprehensive income, net																			Other comprehensive income, net	—			—		—			134			—			134
Recognition of stock-based compensation expense																			Recognition of stock-based compensation expense	—			—		3,011			—			—			3,011
Restricted stock award grants, net of forfeitures																			Restricted stock award grants, net of forfeitures	1,675,472			2		(2)			—			—			—
Issuance of common shares to Hanmi Pharmaceutical Co., Ltd.																			Issuance of common shares to Hanmi Pharmaceutical Co., Ltd.	12,500,000			12		19,988			—			—			20,000
Issuance of common stock upon vesting of performance units																			Issuance of common stock upon vesting of performance units	150,000			—		—			—			—			—
Balance as of March 31, 2022																			Balance as of March 31, 2022	178,827,485			$	179	$	1,117,350		$	(2,908)		$	(1,059,365)		$	55,256
Net loss	Net loss	—	—		—				—			(35,697)				(35,697)			Net loss	—			—		—			—			(29,048)			(29,048)
Other comprehensive loss, net	Other comprehensive loss, net	—	—		—				(1,678)			—				(1,678)			Other comprehensive loss, net	—			—		—			(47)			—			(47)
Recognition of stock-based compensation expense	Recognition of stock-based compensation expense	—	—		4,212				—			—				4,212			Recognition of stock-based compensation expense	—			—		2,077			—			—			2,077
Issuance of common shares under an at-the-market sales agreement		5,678,893	6		21,351				—			—				21,357
Restricted stock award grants, net of forfeitures		1,966,333	2		—				—			—				2
Balance as of March 31, 2021		153,728,336	$	154	$	1,046,784			$	(3,507)		$	(920,992)			$	122,439
Net loss		—	—		—				—			(50,132)				(50,132)
Other comprehensive income, net		—	—		—				180			—				180
Recognition of stock-based compensation expense		—	—		4,360				—			—				4,360
Issuance of common shares under an at-the-market sales agreement		10,172,498	10		31,255				—			—				31,265
Issuance of common stock upon exercise of stock options		1,250	—		2				—			—				2
Issuance of common shares pursuant to at-the-market offering, net of offering costs																			Issuance of common shares pursuant to at-the-market offering, net of offering costs	5,619,827			6		4,941			—			—			4,947
Issuance of common stock for employee stock purchase plan	Issuance of common stock for employee stock purchase plan	163,463	—		474				—			—				474			Issuance of common stock for employee stock purchase plan	388,541			—		257			—			—			257
Restricted stock award grants, net of forfeitures	Restricted stock award grants, net of forfeitures	39,127	—		—				—			—				—			Restricted stock award grants, net of forfeitures	34,420			—		—			—			—			—
Issuance of common stock upon vesting of restricted stock units		1,386	—		—				—			—				—
Balance as of June 30, 2021		164,106,060	$	164	$	1,082,875			$	(3,327)		$	(971,124)			$	108,588

Balance as of June 30, 2022																			Balance as of June 30, 2022	184,870,273			$	185	$	1,124,625		$	(2,955)		$	(1,088,413)		$	33,442
Net loss	Net loss	—	—		—				—			(33,084)				(33,084)			Net loss	—			—		—			—			(21,925)			(21,925)
Other comprehensive income, net	Other comprehensive income, net	—	—		—				(154)			—				(154)			Other comprehensive income, net	—			—		—			(54)			—			(54)
Recognition of stock-based compensation expense	Recognition of stock-based compensation expense	—	—		4,114				—			—				4,114			Recognition of stock-based compensation expense	—			—		2,547			—			—			2,547

Issuance of common shares pursuant to at-the-market offering, net																			Issuance of common shares pursuant to at-the-market offering, net	18,894,118			19		21,594			—			—			21,613

Restricted stock award grants, net of forfeitures	Restricted stock award grants, net of forfeitures	(148,160)	—		—				—			—				—			Restricted stock award grants, net of forfeitures	(424,735)			(1)		—			—			—			(1)
Issuance of warrants upon debt financing																			Issuance of warrants upon debt financing	—			—		230			—			—			230

Balance as of September 30, 2021		163,957,900	$	164	$	1,086,989			$	(3,481)		$	(1,004,208)			$	79,464

Balance as of September 30, 2022																			Balance as of September 30, 2022	203,339,656			$	203	$	1,148,996		$	(3,009)		$	(1,110,338)		$	35,852

Table of Contents


		Common Stock			Additional Paid-In Capital				Accumulated Other Comprehensive Loss			Accumulated Deficit				Total Stockholders' Equity				Common Stock					Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Stockholders' Equity
		Shares	Amount								Shares								Amount
Balance as of December 31, 2019		113,299,612	$	113			$	918,205						$	(3,498)			$	(724,427)		$	190,393
Balance as of December 31, 2020																			Balance as of December 31, 2020	146,083,110			$	146		$	1,021,221		$	(1,829)		$	(885,295)		$	134,243
Net loss	Net loss	—	—		—				—			(40,572)				(40,572)			Net loss	—			—		—			—			(35,697)			(35,697)
Other comprehensive loss, net	Other comprehensive loss, net	—	—		—				(1,329)			—				(1,329)			Other comprehensive loss, net	—			—		—			(1,678)			—			(1,678)
Recognition of stock-based compensation expense	Recognition of stock-based compensation expense	—	—		5,010				—			—				5,010			Recognition of stock-based compensation expense	—			—		4,212			—			—			4,212
Issuance of common stock to 401(k) plan for employees		96,959	—		265				—			—				265

Issuance of common shares under an at-the-market sales agreement																			Issuance of common shares under an at-the-market sales agreement	5,678,893			6		21,351			—			—			21,357
Restricted stock award grants, net of forfeitures	Restricted stock award grants, net of forfeitures	1,377,508	1		—				—			—				1			Restricted stock award grants, net of forfeitures	1,966,333			2		—			—			—			2
Balance as of March 31, 2020		114,774,079	$	114	$	923,480			$	(4,827)		$	(764,999)			$	153,768

Balance as of March 31, 2021																			Balance as of March 31, 2021	153,728,336			$	154	$	1,046,784		$	(3,507)		$	(920,992)		$	122,439
Net loss	Net loss	—	—		—				—			(32,085)				(32,085)			Net loss	—			—		—			—			(50,132)			(50,132)
Other comprehensive income, net	Other comprehensive income, net	—	—		—				1,573			—				1,573			Other comprehensive income, net	—			—		—			180			—			180
Recognition of stock-based compensation expense	Recognition of stock-based compensation expense	—	—		3,988				—			—				3,988			Recognition of stock-based compensation expense	—			—		4,360			—			—			4,360
Issuance of common shares under an at-the-market sales agreement		1,024,286	1		3,070				—			—				3,071

Issuance of common stock for employee stock purchase plan	Issuance of common stock for employee stock purchase plan	98,362	—		282				—			—				282			Issuance of common stock for employee stock purchase plan	163,463			—		474			—			—			474
Issuance of common stock upon exercise of stock options																			Issuance of common stock upon exercise of stock options	1,250			—		2			—			—			2
Restricted stock award grants, net of forfeitures	Restricted stock award grants, net of forfeitures	1,926,385	3		(3)				—			—				—			Restricted stock award grants, net of forfeitures	39,127			—		—			—			—			—
Issuance of common stock upon vesting of restricted stock units	Issuance of common stock upon vesting of restricted stock units	861	—		—				—			—				—			Issuance of common stock upon vesting of restricted stock units	1,386			—		—			—			—			—
Balance as of June 30, 2020		117,823,973	$	118	$	930,817			$	(3,254)		$	(797,084)			$	130,597
Issuance of common shares under an at-the-market sales agreement																			Issuance of common shares under an at-the-market sales agreement	10,172,498			10		31,255			—			—			31,265
Balance as of June 30, 2021																			Balance as of June 30, 2021	164,106,060			$	164	$	1,082,875		$	(3,327)		$	(971,124)		$	108,588
Net loss	Net loss	—	—		—				—			(48,452)				(48,452)			Net loss	—			—		—			—			(33,084)			(33,084)
Other comprehensive income, net		—	—		—				530			—				530
Other comprehensive loss, net																			Other comprehensive loss, net	—			—		—			(154)			—			(154)
Recognition of stock-based compensation expense	Recognition of stock-based compensation expense	—	—		4,108				—			—				4,108			Recognition of stock-based compensation expense	—			—		4,114			—			—			4,114
Issuance of common stock from public offering, net		24,916,667	25		69,708				—			—				69,733
Issuance of common shares pursuant to at-the-market offering, net		2,926,112	3		11,828				—			—				11,831
Issuance of common stock upon exercise of stock options		3,542	—		13				—			—				13

Restricted stock award grants, net of forfeitures	Restricted stock award grants, net of forfeitures	260,878	—		—				—			—				—			Restricted stock award grants, net of forfeitures	(148,160)			—		—			—			—			—

Balance as of September 30, 2020		145,931,172	$	146	$	1,016,474			$	(2,724)		$	(845,536)			$	168,360

Balance as of September 30, 2021																			Balance as of September 30, 2021	163,957,900			$	164	$	1,086,989		$	(3,481)		$	(1,004,208)		$	79,464

See accompanying notes to these unaudited condensed consolidated financial statements.

Table of Contents

SPECTRUM PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended September 30,
	2022		2021
Cash Flows From Operating Activities:
Loss from continuing operations	$	(66,376)	$	(118,686)
Loss from discontinued operations, net of income taxes	(39)		(227)
Net loss	(66,415)		(118,913)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	200		212
Amortization of debt discount	17		—
Stock-based compensation	7,635		12,686
Non-cash lease expense	539		1,151
Other non-cash items	88		281
Loss on disposal of manufacturing equipment	—		3,057
Loss on disposal of assets	2		—
Realized loss (gain) on sale of equity holdings	1,094		(4,580)
Unrealized loss on equity holdings	3,352		12,816
Changes in operating assets and liabilities:
Accounts receivable, net	—		66
Other receivables	431		(1,391)

Inventories	(9,373)		—
Prepaid expenses and other current assets	(617)		1,620
Other assets	976		(89)
Accounts payable and other accrued liabilities	389		4,376
Accrued payroll and benefits	(4,360)		(1,085)
Other long-term liabilities	(5,609)		654
Net cash used in operating activities	(71,651)		(89,139)
Cash Flows From Investing Activities:
Proceeds from maturities of investments	2,799		109,771
Proceeds from sale of equity holdings	2,028		4,406
Purchases of investments	(41,023)		(16,568)
Purchases of property and equipment, net	(45)		(140)
Net cash (used in) provided by investing activities	(36,241)		97,469
Cash Flows From Financing Activities:
Issuance of common shares to Hanmi Pharmaceutical Co., Ltd.	20,000		—
Proceeds from the issuance of debt, net of debt issuance costs	28,852		—
Proceeds from sale of common stock under an at-the-market sales agreement, net	26,560		52,622
Proceeds from sale of stock under our employee stock purchase plan	257		474
Proceeds from employees for exercises of stock options	—		4
Net cash provided by financing activities	75,669		53,100
Effect of exchange rates on cash and cash equivalents	(61)		(4)
Net (decrease) increase in cash and cash equivalents	(32,284)		61,426
Cash and cash equivalents—beginning of period	88,539		46,009
Cash and cash equivalents—end of period	$	56,255	$	107,435
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases	$	1,492	$	1,626
Cash paid for income taxes	$	—	$	12



Supplemental disclosures of non-cash financing activity:
Issuance of warrants in connection with debt financing	$	230	$	—
Debt issuance costs in accrued liabilities	$	152	$	—

Nine Months Ended
September 30,
2021 2020
Cash Flows From Operating Activities:
Loss from continuing operations $ (118,686) $ (121,364)
Income (loss) from discontinued operations, net of income taxes (227) 255
Net loss (118,913) (121,109)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 212 (105)
Stock-based compensation 12,686 13,371
Loss on disposal of manufacturing equipment 3,057 —
Non-cash lease expense 1,151 1,148
Other non-cash items 281 585
Realized gain on sale of equity holdings (4,580) (678)
Unrealized loss on equity holdings 12,816 16,029
Changes in operating assets and liabilities:
Accounts receivable, net 66 1
Other receivables (1,391) 6,370
Prepaid expenses and other current assets 1,620 (2,663)
Other assets (89) 6
Accounts payable and other accrued liabilities 4,376 426
Accrued payroll and benefits (1,085) 427
Other long-term liabilities 654 (2,134)
Net cash used in operating activities (89,139) (88,326)
Cash Flows From Investing Activities:
Proceeds from maturities of investments 109,771 94,929
Proceeds from sale of equity holdings 4,406 1,843
Purchases of investments (16,568) (73,581)
Purchases of property and equipment, net (140) (6,991)
Net cash provided by investing activities 97,469 16,200
Cash Flows From Financing Activities:
Proceeds from sale of common stock, net of offering expenses — 69,733
Proceeds from sale of common stock under an at-the-market sales agreement, net 52,622 14,902
Proceeds from sale of stock under our employee stock purchase plan 474 283
Proceeds from employees for exercises of stock options 4 13
Net cash provided by financing activities 53,100 84,931
Effect of exchange rates on cash and cash equivalents (4) (91)
Net increase in cash and cash equivalents 61,426 12,714
Cash and cash equivalents—beginning of period 46,009 64,418
Cash and cash equivalents—end of period $ 107,435 $ 77,132
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases $ 1,626 $ 1,805
Cash paid for income taxes $ 12 $ 14
Noncash investing activities:
Additions of property and equipment that remain in accounts payable and other accrued liabilities $ — $ 6,017

See accompanying notes to these unaudited condensed consolidated financial statements.

Table of Contents

Spectrum Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

Note 1. Description of Business, Basis of Presentation, And Operating Segment

(a) Description of Business

Spectrum Pharmaceuticals, Inc. (“~~Spectrum”,~~Spectrum,” the ~~“Company”, “we”, “our”,~~“Company,” “we,” “our,” or “us”) is a biopharmaceutical company with a ~~primary~~ strategy ~~comprised~~ of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house ~~development~~ organization includes clinical development, regulatory, quality, data management, and ~~data management.~~commercialization.

We have ~~3 drugs~~one commercial asset and one drug in late-stage development:

•~~ROLONTIS,~~ROLVEDONTM (formerly known as eflapegrastim), a novel long-acting granulocyte colony-stimulating factor (“G-CSF”) for the treatment of chemotherapy-induced neutropenia. ~~We submitted a~~On April 11, 2022, we announced that we had received notice that the Biologics License Application (“BLA”) ~~for ROLONTIS in December 2019,~~had been accepted and ~~in August 2021, we~~ received a ~~Complete Response Letter from~~Prescription Drug User Fee Act (“PDUFA”) date of September 9, 2022. On September 9, 2022, we received the U.S. Food and Drug ~~Administration (the “FDA”~~Administration’s (“FDA”) ~~regarding our Biologics License Application (“BLA”), citing deficiencies related to manufacturing~~marketing approval; and indicating that a reinspection will be necessary. We are currently working on remediating the manufacturing deficiencies and expect that this work will be complete in the fourth quarter of 2021 and plan to resubmit thereafter;

•Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations. AOn December 6, 2021, we announced we submitted our New Drug Application (“NDA”) ~~based on data from Cohort 2 of ZENITH20, which evaluated~~for poziotinib to the FDA for use in patients with previously treated ~~patients with~~locally advanced or metastatic NSCLC with HER2 exon 20 insertion ~~mutation,~~mutations. The NDA submission is ~~expected to be filed~~based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. The product has received Fast Track designation and there is currently no treatment specifically approved by the FDA for this indication. On February 11, 2022, we announced that we had received notice that the NDA had been accepted and received a PDUFA action date of November 24, 2022. On September 22, 2022, we met with the ~~FDA in 2021; and~~FDA’s Oncologic Drugs Advisory Committee (“ODAC”). ODAC voted 9-4 that the current benefits of poziotinib did not outweigh its risks.

•~~Anti-CD20-IFNα, an antibody-interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma patients.~~

Our business strategy is the development of ~~our~~ late-stage assets through commercialization and the sourcing of additional assets that are synergistic with our existing portfolio (through purchase acquisitions, in-licensing transactions, or co-development and marketing arrangements).

(b) Basis of Presentation

Interim Financial Statements

The interim financial data for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021 is unaudited and is not necessarily indicative of our operating results for a full year. ~~In the opinion of our management,~~We believe the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three and nine months ended September 30, ~~2021~~2022 and ~~2020.~~2021. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. Certain prior period amounts have been reclassified for consistency with the current year presentation. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included within our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021 (filed with the SEC on March ~~31, 2021)~~17, 2022).

Discontinued Operations - Sale of our Commercial Product Portfolio

In March 2019, we completed the sale of our ~~7 then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN~~Commercial Product Portfolio (as defined below in , Note 8~~MARQIBO, BELEODAQ, and EVOMELA (the “Commercial Product Portfolio”~~) to Acrotech Biopharma LLC (“Acrotech”) (the “Commercial Product Portfolio Transaction”). ~~Upon closing, we received $158.8 million in~~In accordance with applicable GAAP (ASC 205-20, Presentation of Financial Statements), the revenue-deriving activities and allocable expenses of our sold commercial operations, connected to the Commercial Product Portfolio, are separately classified as “discontinued” for all periods presented

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

~~an upfront cash payment. We are also entitled to receive up to an aggregate~~within the accompanying Condensed Consolidated Statements of ~~$140 million upon Acrotech's future achievement of certain regulatory milestones (totaling $40 million) and sales-based milestones (totaling $100 million) relating to~~Operations. See Note 8 for further information on the Commercial Product ~~Portfolio.~~Portfolio Transaction.

Principles of Consolidation

The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. Substantially all of the accumulated other comprehensive loss is comprised of foreign currency translation adjustments at September 30, ~~2021.~~2022.

Liquidity and Capital Resources

WeThe Company expects to incur future net losses as it continues to fund the advancement and commercialization of its product candidates. Based upon our current projections, including our intention to continue to place a disciplined focus on streamlining our business operations, we believe that our ~~$133.6~~$100.3 million in aggregate cash, cash equivalents and marketable securities as of September 30, ~~2021, are~~2022, will be sufficient to fund our current and planned operations for at least the next twelve months. WeHowever, should our costs and expenses prove to be greater than we currently anticipate, or should we change our current business plan in a manner that increases or accelerates our anticipated costs and expenses, we may ~~however,~~ require additional liquidity ~~as we continue to execute our business strategy, and in connection with opportunistic acquisitions or licensing arrangements. We anticipate that to~~earlier than expected. To the extent ~~that~~it becomes necessary to raise additional cash in the future, we ~~require additional liquidity,~~will seek to raise it ~~will be funded~~ through ~~additional~~the public or private sale of debt or equity securities, out-licensing arrangements, funding from joint-venture or strategic partners, debt ~~financings,~~financing or ~~out-licensing arrangements.~~short-term loans, or through a combination of the foregoing. However, we do not currently have any binding commitments for additional financing. Accordingly, we cannot provide any assurance that we will be able to obtain ~~this~~ additional liquidity on terms favorable to us or our current stockholders, ifor at all. ~~Additionally, our~~Our liquidity and our ability to fund our capital requirements going forward are ~~also~~ dependent, in part, on ~~our future financial performance which is subject to various~~ market and economic factors that are beyond our control. The Company may never achieve profitability or generate positive cash flows, and unless and until it does, the Company will continue to need to raise additional capital.

On September 21, 2022, we entered into a Loan and Security Agreement (“Loan Agreement”), by and among the Company, Allos Therapeutics, Inc., Talon Therapeutics, Inc., and Spectrum Pharmaceuticals International Holdings, LLC, as borrowers (together with the Company, the “Borrowers”), SLR Investment Corp. (“SLR”), as administrative agent (the “Agent”), and the lenders party thereto (the “Lenders”) that provides for a five-year senior secured term loan facility in an aggregate principal amount of up to $65.0 million available to us in four tranches (collectively, the “Term Loans”). As of September 30, 2022, we have drawn a total of $30.0 million of the Term Loans pursuant to the Loan Agreement, with a remaining undrawn principal balance of $35.0 million, which is available through December 31, 2023 and is subject to the achievement of certain milestone events. Refer to Note 5 for additional information.

We operate 1one reportable operating segment that is focused exclusively on developing ~~(and eventually marketing)~~and marketing oncology and hematology drug products. For the three and nine months ended September 30, ~~2021~~2022 and ~~2020,~~2021, all of our ~~revenues and~~ operating costs and expenses were solely attributable to these activities (and as applicable, classified as “discontinued” within the accompanying Condensed Consolidated Statements of Operations).

Note 2. Summary of Significant Accounting Policies And Use of Estimates

The preparation of financial statements in conformity with GAAP requires our management to make ~~informed~~ estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an on-going basis, our management evaluates (as applicable) its most critical estimates and assumptions, including those related to: (i) the realization of our tax assets and estimates of our tax liabilities; (ii) the fair value of our investments; (iii) the valuation of our stock options and the periodic expense recognition of stock-based compensation; ~~and~~ (iv) the potential outcome of our ongoing or threatened ~~litigation.~~litigation; and (v) the future undiscounted cash flows and revenues, as well as assesses our ability to fund our operations for at least the next twelve months from the date of issuance of these financial statements.

Our accounting policies and estimates that most significantly impact the presented amounts within these Condensed Consolidated Financial Statements are further described below:

(i) ~~Revenue Recognition~~

~~In March 2019, we completed the Commercial Product Portfolio Transaction. In accordance with applicable GAAP (ASC 205-20, Presentation of Financial Statements~~), the revenue-deriving activities of our sold commercial operation are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations.

~~Required Elements of Our Revenue Recognition~~: ~~Revenue from our (a) product sales, (b) out-license arrangements,~~Cash and ~~(c) service arrangements is recognized under Accounting Standards Update (“ASU~~”) ~~No. 2014-09~~, ~~Revenue from Contracts with Customers~~ (~~“Topic 606”) in a manner that reasonably reflects the delivery of our goods and/or services to customers in return for expected consideration and includes the following elements:~~

~~(1)we ensure that we have an executed contract(s) with our customer that we believe is legally enforceable;~~Cash Equivalents

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

~~(2)we identify the “performance obligations” in the respective contract;~~

~~(3)we determine the “transaction price” for each performance obligation in the respective contract;~~

~~(4)we allocate the transaction price to each performance obligation; and~~

~~(5)we recognize revenue only when we satisfy each performance obligation.~~

~~These five elements, as applied to each of our revenue categories, are summarized below:~~

~~(a)~~ ~~Product Sales~~: We sell our products to pharmaceutical wholesalers/distributors or to our product licensees (i.e., our customers). Our wholesalers/distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from our product sales is recognized as physical delivery of product occurs (when our customer obtains control of the product), in return for agreed-upon consideration.

~~Our gross product sales (i.e., delivered units~~ ~~multiplied by~~ the contractual price per unit) are reduced by our corresponding gross-to-net (“GTN”) estimates using the “expected value” method, resulting in reported “product sales, net” that reflects the amount we ultimately expect to realize in net cash proceeds, taking into account our current period gross sales and related cash receipts, and the subsequent cash disbursements on these sales that we estimate for the various GTN categories discussed below. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred (of some, or all) of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, and distribution, data, and group purchasing organization (“GPO”) administrative fees may be materially above or below the amount estimated, then requiring prospective adjustments to our reported net product sales.

~~These GTN estimate categories (that comprise our GTN liabilities) are each discussed below:~~

~~Product Returns Allowances~~: Our customers are contractually permitted to return certain purchased products within the contractual allowable time before/after the applicable expiration date. Returns outside of this aforementioned criteria are not customarily allowed. We estimate expected product returns using our historical return rates. Returned product is typically destroyed since substantially all are due to imminent expiry and cannot be resold.

~~Government Chargebacks~~: Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers.

~~Prompt Pay Discounts~~: ~~Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage.~~

~~Commercial Rebates~~: Commercial rebates are based on (i) our estimates of end-user purchases through a GPO, (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us.

~~Medicaid Rebates~~: Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in our receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment.

~~Distribution, Data, and GPO Administrative Fees~~: Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales.

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

~~(b)~~ ~~License Fees~~: Our out-license arrangements allow licensees to market our product(s) in certain territories for a specific term (representing the out-license of “functional intellectual property”). These arrangements may include one or more of the following forms of consideration: (i) upfront license fees, (ii) sales royalties, (iii) sales milestone-achievement fees, and (iv) regulatory milestone-achievement fees. We recognize revenue for each based on the contractual terms that establish our right to collect payment once the performance obligation is achieved, as follows:

~~(1) Upfront License Fees:~~ We determine whether upfront license fees are earned at the time of contract execution (i.e., when rights transfer to the customer) or over the actual (or implied) contractual period of the out-license. As part of this determination, we evaluate whether we have any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer. Our customers’ “distinct” rights to licensed “functional intellectual property” at the time of contract execution results in concurrent revenue recognition of all upfront license fees (assuming that there are no other performance obligations at contract execution that are inseparable from this license transfer).

~~(2)~~ ~~Royalties~~: Under the “sales-or-usage-based royalty exception” we recognize revenue in the same period that our licensees complete product sales in their territory for which we are contractually entitled to a percentage-based royalty receipt.

~~(3)~~ ~~Sales Milestones~~: Under the “sales-or-usage-based royalty exception” we recognize revenue in full within the period that our licensees achieve annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt.

~~(4)~~ ~~Regulatory Milestones~~: ~~Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee.~~

•When our licensee is responsible for the achievement of the regulatory milestone, we recognize revenue in full (for the contractual amount due from our licensee) in the period that the approval occurs (i.e., when the “performance obligation” is satisfied by our customer) under the “most likely amount” method. This revenue recognition remains “constrained” (i.e., not recognized) until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment.

•When we are responsible for the achievement of a regulatory milestone, the “relative selling price method” is applied for purposes of allocating the transaction price to our performance obligations. In such case, we consider (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement and (ii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. We have historically assessed the contractual value of these milestones upon their achievement to be identical to the allocation of value of our performance obligations and thus representing the “transaction price” for each milestone at contract inception. We recognize this revenue in the period that the regulatory approval occurs (i.e., when we complete the “performance obligation”) under the “most likely amount” method, and revenue recognition is otherwise “constrained” until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment.

~~(c)~~ ~~Service Revenue: We receive fees under certain arrangements for (i) sales and marketing services, (ii) supply chain services, (iii) research and development services, and (iv) clinical trial management services.~~

Our rights to receive payment for these services may be established by (1) a fixed-fee schedule that covers the term of the arrangement, so long as we meet ongoing performance obligations, (2) our completion of product delivery in our capacity as a procurement agent, (3) the successful completion of a phase of drug development, (4) favorable results from a clinical trial, and/or (5) regulatory approval events.

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

We consider whether revenue associated with these service arrangements is reportable each period, based on our completed services or deliverables (i.e., satisfied “performance obligations”) during the reporting period, and the terms of the arrangement that contractually result in fixed payments due to us. The promised service(s) within these arrangements are distinct and explicitly stated within each contract, and our customer benefits from the separable service(s) delivery/completion. Further, the nature of the promise to our customer as stated within the respective contract is to deliver each named service individually (not a transfer of combined items to which the promised goods or services are inputs), and thus are separable for revenue recognition.

~~(ii) Cash and Cash Equivalents~~

Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date.

~~(iii)~~(ii) Marketable Securities

Marketable securities consist of our holdings in equity securities (including mutual funds), bank CDs, government-related debt securities, and corporate debt securities. For equity securities and mutual funds, any realized ~~gains (losses)~~ or unrealized gains (losses) are recognized in “other income (expense), net” within the Condensed Consolidated Statements of Operations. Debt securities and bank CDs are classified as “available-for-sale” investments and (1) realized gains (losses) are recognized in “other income (expense), net” within the Condensed Consolidated Statements of Operations and (2) unrealized gains (losses) are recognized as a component of “accumulated other comprehensive loss” within the Condensed Consolidated Statements of Stockholders’ Equity.

~~(iv) Accounts Receivable, Net~~(iii) Inventory

Our accounts receivable, net of allowance for credit losses, are derived from our product sales and license fees, and do not bear interest. The allowance for credit losses is management’s best estimate of the amount of expected credit losses in our existing accounts receivable and any anticipated discounts. The allowance for credit losses is adjusted each period through earnings to reflect expected credit losses over the remaining life of the asset. Account balances are written off against the allowance after appropriate collection efforts are exhausted.

~~(v) Inventories~~

We value our inventory at the lower of ~~(i) the actual~~ cost ~~of its purchase~~ or ~~manufacture, or (ii) its~~ net realizable value. Inventory cost is determined on ~~the~~a first-in, first-out ~~method.~~basis. We regularly review our inventory quantities ~~in process of manufacture~~ and ~~on hand. When~~when appropriate we record a provision for obsolete and excess inventory to derive its ~~net realizable value,~~new cost basis, which takes into account our sales forecast ~~by product~~ and corresponding expiry ~~dates of each product lot.~~dates. We have not recognized a provision for obsolete and excess inventory through September 30, 2022.

~~Manufacturing costs of drug products that are pending~~We received FDA approval ~~during clinical~~for ROLVEDON on September 9, 2022, and on that date began capitalizing inventory purchases of saleable product from certain suppliers. Prior to FDA approval, all saleable product purchased from such suppliers were included as a component of research and development ~~and trials, and at-risk~~expense, as we were unable to assert that the inventory ~~build in anticipation of commercialization, are exclusively recognized through “research and development” expense on the accompanying Condensed Consolidated Statements of Operations.~~had future economic benefit until we had received FDA approval.

~~(vi)~~(iv) Property and Equipment, Net

Our property and equipment, net, is stated at historical cost, and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of ~~“long-lived assets”~~long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the net undiscounted cash flows expected to be generated by the asset group. An impairment loss would be recorded for the excess of net carrying value over the fair value of the asset impaired. The fair value is estimated based on expected discounted future cash flows or other methods such as orderly liquidation value based on assumptions of asset class and observed market data. An orderly liquidation value is the amount that could be realized upon liquidation, given a sufficient amount of time to find a purchaser for a sale of assets in their existing condition and location, as of a specific date, and assuming the sale is to market participants who can utilize such assets in their highest and best use. The orderly liquidation values are applied against the carrying values of the assets and the impairment loss is measured as the difference between the liquidation value and the carrying value of the assets.

~~See Note 4(d) for further discussion related to an impairment that occurred during the year ended December 31, 2020.~~

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

~~(vii)~~(v) Stock-Based Compensation

Stock-based compensation expense for equity awards granted to our employees and members of our Board of Directors is recognized on a straight-line basis over each award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited prior to vesting, ~~though~~and is ultimately adjusted for actual forfeitures. We use the Black-Scholes option pricing model to determine the fair value of stock options and stock appreciation rights (as of the date of grant) that have service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) that have combined market conditions and service conditions for vesting.

The recognition of stock-based compensation expense and the initial calculation of stock option fair value requires ~~uncertain~~certain assumptions, including (a) the pre-vesting forfeiture rate of the award, (b) the expected term that the stock option will remain outstanding, (c) our stock price volatility over the expected term (and that of our designated peer group with respect to certain market-based awards), (d) zero dividend yield, and ~~(d)~~(e) the prevailing risk-free interest rate for the period matching the expected term.

With regard to (a)-~~(d)~~(e) above: we estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on the historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Department of the Treasury yields in effect at award grant, for a period equaling the expected term of the stock ~~option.~~option and we estimate a zero dividend yield.

~~(viii)~~

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

(vi) Basic and Diluted Net Loss per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share ~~are~~is the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only stock options, warrants, and other common stock equivalents outstanding during the period to the extent that they are dilutive.

There were ~~12,708,185~~24.2 million shares and ~~9,648,862~~12.7 million shares of outstanding securities (including stock options, restricted stock units, unvested restricted stock awards, stock appreciation rights, and performance awards) as of September 30, ~~2021~~2022 and ~~2020,~~2021, respectively, that were excluded from the calculation of diluted net loss per share because their inclusion would have been anti-dilutive.

~~(ix)~~(vii) Income Taxes

Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

We apply an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods. Our ETR differs from the U.S. federal statutory tax rate primarily as a result of nondeductible expenses and the impact of a valuation allowance on our deferred tax assets, which we record because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made.

In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in ~~“benefit~~“provision for income taxes from continuing operations” within the accompanying Condensed Consolidated Statements of Operations for the period in which we received the notice.

~~In March 2020, we elected to early adopt~~ ~~ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes.~~ ~~ASU 2019-12~~ ~~removes certain exceptions to the general principles in~~ ~~Topic 740~~ ~~and also clarifies and amends existing guidance to improve consistent application.~~

~~(x)~~(viii) Research and Development Expenses

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

Our research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, benefits, and other staff-related costs including associated stock-based compensation, laboratory supplies, clinical trial and related clinical manufacturing costs, costs related to manufacturing preparations, fees paid to other entities that conduct certain research and development activities on our behalf and payments made pursuant to license agreements. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of activities and the invoices received from our external service providers. We adjust our accruals as actual costs become known. Where contingent milestone payments are due to third parties under research and development or license agreements, the milestone payment obligations are expensed ~~when~~in the ~~clinical~~earliest period that we determine the respective milestone achievement is probable or ~~regulatory milestone results~~has occurred.

(ix) Debt Issuance Costs

Debt issuance costs incurred in connection with the Term Loans are ~~achieved.~~classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement. Refer to Note 5 for additional information on the Term Loans.

~~(xi)~~(x) Recently Issued Accounting Standards

There are several new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), which we do not believe had or will have a material impact on our consolidated financial statements, unless otherwise described below.

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value ~~Measurements~~

~~We determine measurement-date fair value based~~Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on ~~the proceeds that would be received through~~ the sale of an equity security is not considered part of the ~~asset, or that we would pay to settle or transfer~~unit of account of the ~~liability,~~equity security and, therefore, is not considered in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measuremeasuring fair value. ~~These tiers include the following:~~This

~~Level 1: Quoted prices (unadjusted)~~

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in ~~active markets~~thousands, except share, per share, interest rate, and number of years)

(Unaudited)

standard becomes effective for ~~identical assets or liabilities that are publicly accessible at the measurement date.~~

~~Level 2: Observable prices that are based~~us on ~~inputs~~January 1, 2024, and is not ~~quoted~~expected to have a material impact on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.

~~Level 3: Unobservable inputs are used when little or no market data is available.~~our condensed consolidated financial statements and related disclosures.

Note 3. Fair Value Measurements

We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.

Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.

Level 3: Unobservable inputs are used when little or no market data is available.

The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among the three fair value measurement categories:
September 30, 2021
Fair Value Measurements
Level 1 Level 2 Level 3 Total
Assets:
Money market funds $ 92,172 $ — $ — $ 92,172
Equity securities 10,237 — — 10,237
Government-related debt securities 10,023 — — 10,023
Mutual funds 5,900 9 — 5,909
Key employee life insurance, cash surrender value(1)
— 4,287 — 4,287
$ 118,332 $ 4,296 $ — $ 122,628
Liabilities:
Deferred executive compensation liability(2)
$ — $ 10,489 $ — $ 10,489
$ — $ 10,489 $ — $ 10,489

~~(1)~~ Included within other assets on our Condensed Consolidated Balance Sheets, and the amount is based on the stated cash surrender value of life insurance policies of named current and former employees at each period-end.

~~(2)~~ Included $1.1 million within accounts payable and other accrued liabilities and $9.4 million within other long-term liabilities on our Condensed Consolidated Balance Sheets. The amounts are based on the period-end market value of mutual fund investments selected by employee participants of the deferred compensation plan.

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~


		December 31, 2020 Fair Value Measurements									September 30, 2022 Fair Value Measurements
		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total
Assets:	Assets:									Assets:
Government-related debt securities		$	92,928	$	—	$	—	$	92,928
Corporate debt securities		—		8,848		—		8,848
Money market funds	Money market funds	40,560		—		—		40,560		Money market funds	$	40,913	$	—	$	—	$	40,913
Equity securities	Equity securities	24,946		—		—		24,946		Equity securities	258		—		—		258
Bank CDs		—		1,721		—		1,721
Government-related debt securities										Government-related debt securities	45,158		—		—		45,158

Mutual funds	Mutual funds	5,573		9		—		5,582		Mutual funds	3,551		8		—		3,559
Key employee life insurance, cash surrender value(1)	Key employee life insurance, cash surrender value(1)	—		3,963		—		3,963		Key employee life insurance, cash surrender value(1)	—		3,504		—		3,504
		$	164,007	$	14,541	$	—	$	178,548		$	89,880	$	3,512	$	—	$	93,392
Liabilities:	Liabilities:									Liabilities:
Deferred executive compensation liability(2)	Deferred executive compensation liability(2)	$	—	$	9,783	$	—	$	9,783	Deferred executive compensation liability(2)	$	—	$	7,434	$	—	$	7,434
		$	—	$	9,783	$	—	$	9,783		$	—	$	7,434	$	—	$	7,434

(1) Included within other assets on our Condensed Consolidated Balance Sheets, and the amount is based on the stated cash surrender value of life insurance policies of named current and former employees at each period-end.

(2) Included ~~$1.3~~$3.8 million within accounts payable and other accrued liabilities and ~~$8.5~~$3.6 million within other long-term liabilities on our Condensed Consolidated Balance Sheets. ~~The~~


	December 31, 2021 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Equity securities	$	5,718	$	—	$	—	$	5,718
Money market funds	66,322		—		—		66,322


Mutual funds	6,390		9		—		6,399

Key employee life insurance, cash surrender value(1)	—		4,507		—		4,507
	$	78,430	$	4,516	$	—	$	82,946
Liabilities:
Deferred executive compensation liability(2)	$	—	$	11,243	$	—	$	11,243
	$	—	$	11,243	$	—	$	11,243

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts ~~are~~presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

(1) Included within other assets on our Condensed Consolidated Balance Sheets, and the amount is based on the ~~period-end market~~stated cash surrender value of ~~mutual fund investments selected by employee participants~~life insurance policies of ~~the deferred compensation plan.~~named current and former employees at each period-end.

(2) Included $2.0 million within accounts payable and other accrued liabilities and $9.2 million within other long-term liabilities on our Condensed Consolidated Balance Sheets.

We did not have any transfers between “Level 1” and “Level 2” measurement categories for any periods presented.

Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and other accrued liabilities approximate their fair values due to their short-term nature of settlement.

Note 4. Balance Sheet Account Detail

The composition of selected financial statement captions that comprise the accompanying Condensed Consolidated Balance Sheets are summarized below:

(a) Cash and Cash Equivalents and Marketable Securities

We maintain cash balances with select major financial institutions. The Federal Deposit Insurance Corporation ~~(FDIC)~~(“FDIC”) and other third parties insure a fraction of these deposits. Accordingly, these cash deposits are not insured against the possibility of a substantial or complete loss of principal and are inherently subject to the credit risk of the corresponding financial institution. ~~There were no material unrealized losses on our investment securities at September 30, 2021 or December 31, 2020.~~

Our investment policy requires that purchased investments may only be in highly-rated and liquid financial instruments and limits our holdings of any single issuer (excluding any debt or equity securities that may be received from our strategic partners in connection with an out-license arrangement).

The carrying amount of our equity securities and money market funds ~~and bank CDs~~ approximates their fair value (utilizing “Level 1” or “Level 2” inputs) because of our ability to immediately convert these instruments into cash with minimal expected change in value. ~~As of~~There were no material unrealized losses on our investment securities at September 30, ~~2021, our held securities that remain in an unrealized loss position for less than one year were insignificant and are presented in the table below.~~2022 or December 31, 2021.

The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:


	Historical or Amortized Cost		Fair Value		Cash and Cash Equivalents		Marketable Securities
September 30, 2022
Money market funds	$	40,913	$	40,913	$	40,913	$	—
Equity securities(1)	—		258		—		258
Government-related debt securities	45,172		45,158		4,970		40,188

Mutual funds	2,146		3,551		—		3,551

Bank deposits	10,372		10,372		10,372		—
Total cash and cash equivalents and marketable securities	$	98,603	$	100,252	$	56,255	$	43,997
December 31, 2021
Equity securities	$	3,512	$	5,718	$	—	$	5,718
Money market funds	66,322		66,322		66,322		—



Bank deposits	22,217		22,217		22,217		—
Mutual funds	5,218		6,390		—		6,390
Total cash and cash equivalents and marketable securities	$	97,269	$	100,647	$	88,539	$	12,108

(1)Our aggregate equity holdings consist of 0.4 million common shares of Unicycive Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $0.3 million as of September 30, 2022. We completed the sale of 0.4 million shares of common stock and recognized a $0.4 million gain within “other expense, net” within the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2022. Additionally, we completed the sale of our remaining 0.9 million shares of CASI Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, common stock and recognized a $1.9 million loss within “other expense, net” within the accompanying Condensed

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

Consolidated Statements of Operations for the nine months ended September 30, 2022. We no longer hold any shares of CASI Pharmaceuticals, Inc.

(b) Inventories

Upon approval of ROLVEDON on September 9, 2022, we began capitalizing our purchases of saleable inventory of ROLVEDON from suppliers. Inventories consist of the following:


	September 30, 2022		December 31, 2021
Raw materials	$	9,000	$	—
Work-in-process	373		—
Finished goods	—		—
Inventories	$	9,373	$	—

“Accounts payable and other accrued liabilities” consists of the following:


	September 30, 2022		December 31, 2021
Trade accounts payable and other	$	35,005	$	33,408
Lease liability - current portion	752		1,282







Commercial Product Portfolio accruals (Note 8)	6,254		6,568
Accounts payable and other accrued liabilities	$	42,011	$	41,258

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of gross-to-net (“GTN”) estimates related to the Commercial Product Portfolio accruals were as follows:


	Commercial/Medicaid Rebates and Government Chargebacks		Distribution, Data, Inventory and GPO Administrative Fees		Product Return Allowances		Total
Balance as of December 31, 2020	$	2,601	$	942	$	4,299	$	7,842

(Less): Payments and credits against GTN accruals	(1,159)		—		(115)		(1,274)
Balance as of December 31, 2021	1,442		942		4,184		6,568

(Less): Payments and credits against GTN accruals	(50)		—		(264)		(314)
Balance as of September 30, 2022	$	1,392	$	942	$	3,920	$	6,254

Note 5. Loan Payable

On September 21, 2022, we entered into the Loan Agreement that provides for a five-year senior secured term loan facility in an aggregate principal amount of up to $65.0 million, available to us in four tranches. Upon entering into the Loan Agreement in September 2022, we borrowed $30.0 million in term loans (the “Term A Loan”). Under the terms of the Loan Agreement, we may borrow up to an additional $35.0 million in term loans subject to us achieving the following milestones:

a.Through December 20, 2022, $10.0 million (the “Term B Loan”) if we provide satisfactory evidence that the FDA has approved the New Drug Application (“NDA”) for poziotinib for non-small cell lung cancer in previously treated patients with HER2 exon 20 insertion mutations with a label materially consistent with our filing of such NDA;

b.Through May 15, 2023, $15.0 million (the “Term C Loan”) if we provide satisfactory evidence that we have achieved a minimum of $15.7 million in Net Product Revenue (as defined in the Loan Agreement) calculated on a trailing six (6) month basis for any measuring period ending on or prior to March 31, 2023; and

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

c.Through November 15, 2023, $10.0 million (the “Term D Loan”) if we provide satisfactory evidence that we have achieved a minimum of $40.0 million in Net Product Revenue calculated on a trailing six (6) month basis for any measuring period ending on or prior to September 30, 2023.

The Loan Agreement contains customary events of default and representations, warranties and affirmative and negative covenants, including financial covenants requiring the Company to (i) maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent of at least $25.0 million at all times commencing from September 21, 2022 and ending on the later of (A) July 31, 2023 and (B) the date Company either (1) receives, on or after September 13, 2022, at least $40.0 million in net cash proceeds from equity raises and/or business development or collaboration agreements or (2) (x) receives, on or after September 13, 2022, at least $30.0 million in net cash proceeds from equity raises and/or business development or collaboration agreements and (y) achieves at least $25.8 million in trailing 6-month net revenue from the sale of any products (on or prior to the period ending July 31, 2023) and (ii) maintain, commencing March 31, 2023, on a monthly basis until the end of 2023, and on a quarterly basis thereafter, either (A) net revenue from the sale of any products of at least $100 million on a trailing 12-month basis, or (B) net revenue from the sale of any products of an amount set forth in the Loan Agreement, on a trailing 6-month basis.

The Term Loans will be guaranteed by certain of our subsidiaries (the “Guarantors”). Our obligations under the Loan Agreement are secured by a pledge of substantially all of our assets and will be secured by a pledge of substantially all of the assets of the Guarantors.

The Term Loans bear interest at a floating rate per annum equal to the 1-Month CME Term SOFR (subject to a 2.3% floor) plus 5.7%. Interest-only payments are due beginning on November 1, 2022 through September 30, 2025, and the interest-only period may be extended to September 30, 2026 (“Principal Extension”) provided the Company and its subsidiaries have achieved a minimum of $40.0 million in net product revenue on a trailing six-month basis for any measuring period ending on or prior to September 30, 2023. We are also required to make monthly principal payments beginning on October 1, 2025 in an amount equal to 1/24th of the aggregate amount of the Term Loans outstanding if the Principal Extension is not executed, or, beginning on October 1, 2026, 1/12th of the aggregate amount of the Term Loans outstanding if the Principal Extension is executed. On the Maturity Date, we are required to pay in full all outstanding Term Loans and other amounts owed under the Loan Agreement.

At the time of borrowing any tranche of the Term Loans, we are required to pay an upfront fee of 1.0% of the aggregate principal amount borrowed at that time. We may prepay all of the Term Loans, and are required to make mandatory prepayments of the Term Loans upon the occurrence of a bankruptcy or insolvency event (including the acceleration of claims by operation of law). All mandatory and voluntary prepayments of the Term Loans are subject to prepayment premiums equal to (i) 3% of the principal prepaid if prepayment occurs on or before September 21, 2023, (ii) 2% of the principal prepaid if prepayment occurs after September 21, 2023 but on or before September 21, 2024, or (iii) 1% of the principal prepaid if prepayment occurs after September 21, 2024.

We will pay facility fees and success fees upon borrowing the future tranches as follows:

a.Facility fee of $0.1 million and success fee of 0.75% of the principal of the Term B Loans,

b.Facility fee of $0.2 million and success fee of 0.75% of the principal of the Term C Loans, and

c.Facility fee of $0.1 million and success fee of 0.75% of the principal of the Term D Loans.

In addition, we are required to pay an exit fee in an amount equal to 4.75% of all principal repaid, whether as a mandatory prepayment, voluntary prepayment, or a scheduled repayment. In connection with the Loan Agreement, we granted warrants (“Warrants”) to the Lenders to purchase up to 454,454 shares of our common stock at an exercise price of $0.66 per share, which had a fair market value at time of issuance of $0.2 million. The number of shares and exercise price are subject to anti-dilution adjustments for splits, dividends, capital reorganizations, reclassifications and similar transactions. Upon borrowing the future tranches, we will issue warrants to the Lenders to purchase an aggregate number of shares of common stock equal to 1.0% of the Term Loan amount funded divided by the applicable Exercise Price (as defined below). The Exercise Price is defined as the lesser of (a) the 10-day trailing average of the Company’s closing common stock price ending on the trading day immediately prior to the funding date of the applicable Term Loan and (b) the Company’s closing common stock price on the trading day immediately prior to the funding date of the applicable Term Loan. The Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance. During our evaluation of equity classification for the Warrants, we considered the conditions as prescribed within ASC 815-40, Derivatives and Hedging, Contracts in an Entity’s own Equity. The Warrants do not fall under the liability criteria within ASC 480, Distinguishing

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

Historical or Amortized Cost Fair
Value Cash and Cash
Equivalents Marketable
Securities
September 30, 2021
Money market funds $ 92,172 $ 92,172 $ 92,172 $ —
Equity securities(1)
3,528 10,237 — 10,237
Government-related debt securities 10,023 10,023 — 10,023
Mutual funds 4,753 5,900 — 5,900
Bank deposits 15,263 15,263 15,263 —
Total cash and cash equivalents and marketable securities $ 125,739 $ 133,595 $ 107,435 $ 26,160
December 31, 2020
Money market funds $ 40,560 $ 40,560 $ 40,560 $ —
Equity securities 3,764 24,946 — 24,946
Government-related debt securities 92,881 92,928 — 92,928
Corporate debt securities 8,846 8,848 — 8,848
Mutual funds 4,497 5,573 — 5,573
Bank CDs 1,715 1,721 — 1,721
Bank deposits 5,449 5,449 5,449 —
Total cash and cash equivalents and marketable securities $ 157,712 $ 180,025 $ 46,009 $ 134,016

~~(1)~~Liabilities from Equity ~~Our aggregate equity holdings consist~~as they are not puttable and do not represent an instrument that has a redeemable underlying security. The Warrants do meet the definition of ~~6.7 million common shares of CASI Pharmaceuticals, Inc.,~~ a ~~NASDAQ-listed biopharmaceutical company, with a fair market value of $7.9 million~~derivative instrument under ASC 815, but are eligible for the scope exception as ~~of September 30, 2021. We completed the sale of 1.8 million shares of~~they are indexed to our common stock and ~~recognized a $4.2 million gain within “other expense, net” within~~would be classified in permanent equity if freestanding.

The Loan Agreement contains customary events of default that entitle SLR to accelerate the ~~accompanying Condensed Consolidated Statements~~repayment of ~~Operations~~the Term Loans, and to exercise remedies against the Borrowers and the collateral securing the Term Loans. Upon the occurrence and for the ~~nine months ended~~duration of an event of default, an additional default interest rate of 4.0% will apply to all obligations owed under the Loan Agreement.

In September ~~30, 2021. Additionally,~~2022, we ~~hold 0.8~~borrowed $30.0 million ~~common shares of Unicycive Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $2.3 million as of September 30, 2021.~~

~~(b) Other Receivables~~

~~“Other receivables” consists~~upon the signing of the ~~following:~~

September 30, 2021 December 31, 2020
Other miscellaneous receivables $ 2,443 $ 901
Income tax receivable - current portion 1,297 1,297
Interest receivable from marketable securities 123 196
Other receivables $ 3,863 $ 2,394

~~(c) Prepaid Expenses~~Loan Agreement and ~~Other Current Assets~~

~~“Prepaid expenses~~incurred debt issuance costs of $3.0 million, including the exit fee of $1.4 million, that are classified as contra-liabilities on our condensed consolidated balance sheets and ~~other current assets” consists~~are being recognized as interest expense over the term of the ~~following:~~

September 30, 2021 December 31, 2020
Prepaid expenses and deferred costs $ 2,370 $ 1,996
Prepaid insurance 170 2,165
Prepaid expenses and other current assets $ 2,540 $ 4,161

~~(d) Property and Equipment, net~~

~~“Property and equipment, net” consists of~~loan using the ~~following:~~

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share,~~effective interest ~~rate, and number of years)~~

~~(Unaudited)~~

September 30, 2021 December 31, 2020
Manufacturing equipment $ — $ 3,245
Computer hardware and software 1,802 1,680
Laboratory equipment 5 5
Leasehold improvements 1,267 1,267
Office furniture 307 248
Property and equipment, at cost 3,381 6,445
(Less): Accumulated depreciation (2,874) (2,868)
Property and equipment, net $ 507 $ 3,577

~~Depreciation expense was immaterial for~~method. During the three and nine months ended September 30, ~~2021 and 2020, respectively.~~2022, we recognized interest expense related to the Term Loans of approximately $0.1 million, approximately $17 thousand of which was noncash.

The following table summarizes the composition of Term Loans payable as reflected on the condensed consolidated balance sheet as of September 30, 2022 (in thousands):

Manufacturing equipment was comprised of our owned ROLONTIS production equipment on location at our contract manufacturer. As of December 31, 2020, we determined that we would no longer proceed with the technology transfer and validation of a second manufacturing source for ROLONTIS and communicated this decision to the second source manufacturer. We had invested significant capital to prepare this facility for production. Due to the decision to halt this work, we determined that the value of certain ROLONTIS production equipment had a carrying amount in excess of the anticipated recoverable value as there would be no future cash flows from these assets other than through the sale of this equipment. We determined the fair value of these assets under an orderly liquidation value method, and based on the valuation performed we recorded an impairment of $19.7 million to our carrying value for this equipment, which was recorded as research and development expense for the year ended December 31, 2020 within the Consolidated Statements of Operations. During the three months ended September 30, 2021, this equipment was surrendered in connection with the termination of our agreement with our second source manufacturer and we recorded incremental research and development expense of $2.9 million. Fair value was based on observable market data (“Level 2”). Due to the specialized nature of this production equipment, adjustments to observable market data were applied (“Level 3”).

~~(e) Accounts Payable and Other Accrued Liabilities~~

~~“Accounts payable and other accrued liabilities” consists of the following~~:
September 30, 2021 December 31, 2020
Trade accounts payable and other $ 40,914 $ 34,385
Lease liability - current portion 1,451 1,544
Commercial Product Portfolio accruals (Note 7) 6,617 7,842
Accounts payable and other accrued liabilities $ 48,982 $ 43,771

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates related to the Commercial Product Portfolio accruals were as follows:

Commercial/Medicaid Rebates and Government Chargebacks Distribution, Data, Inventory and
GPO Administrative Fees Product Return Allowances Total
Balance as of December 31, 2019 $ 14,671 $ 1,138 $ 4,714 $ 20,523
(Less): Payments and credits against GTN accruals (12,070) (196) (415) (12,681)
Balance as of December 31, 2020 $ 2,601 $ 942 $ 4,299 $ 7,842
(Less): Payments and credits against GTN accruals (1,160) — (65) (1,225)
Balance as of September 30, 2021 $ 1,441 $ 942 $ 4,234 $ 6,617


	September 30, 2022
Gross proceeds	$	30,000
Accrued exit fee	1,425
Unamortized debt discount	(2,937)
Carrying value	$	28,488

The aggregate maturities of Loan Payable as of September 30, 2022 are as follows (in thousands):


	September 30, 2022
2022	$	—
2023	—
2024	—
2025	3,750
2026 and thereafter	26,250
	$	30,000

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

Note 5.6. Stock-Based Compensation

In June 2018, we adopted the 2018 Long-Term Incentive Plan (the “2018 Plan”) which ~~provided~~provides for the issuance of restricted stock awards and units, incentive and nonqualified stock options, performance unit awards, stock appreciation rights, and other stock-based awards to employees, consultants and members of our Board of Directors. On June 21, 2022, our shareholders approved an additional 18.0 million shares to be reserved for issuance under the 2018 Plan.

Stock-based award grants to employees generally vest one-third on the first anniversary of the date of grant, and in equal annual installments thereafter over the remaining two-year vesting period. The 2018 Plan limits the term of each stock option to no more than 10 years from the date of grant. Historically, in the event of a change in control, all award types, with the exception of performance unit awards made to Named Executive Officers (“NEOs”) and staff, would automatically vest in full effective as of immediately prior to the consummation of the change in control. Moving forward, in the event of a change in control, all future award grants made to staff will vest at the full discretion of the Compensation Committee. All future award grants made to NEOs shall be governed by the terms of each individual Executive Employment Agreement, which typically provide that, with the exception of performance unit awards, all award types vest in full immediately prior to the consummation of a change in control.

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

We report our stock-based compensation expense (inclusive of our incentive stock plan and employee stock purchase plan) in the accompanying Condensed Consolidated Statements of Operations within “total operating costs and expenses” for the three and nine months ended September 30, ~~2021~~2022 and ~~2020,~~2021, as follows:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2022		2021		2022		2021

Selling, general and administrative	Selling, general and administrative	$	2,927	$	3,018	$	8,730	$	9,773	Selling, general and administrative	$	1,477	$	2,927	$	4,589	$	8,730
Research and development	Research and development	1,187		1,090		3,956		3,598		Research and development	1,070		1,187		3,046		3,956
Total stock-based compensation	Total stock-based compensation	$	4,114	$	4,108	$	12,686	$	13,371	Total stock-based compensation	$	2,547	$	4,114	$	7,635	$	12,686

~~We granted 3.5 million~~Restricted Stock Awards and Units

The following table summarizes activity related to restricted stock ~~options with a weighted average exercise price of $3.65 during~~awards (“RSAs”) for the nine months ended September 30, ~~2021. At September 30, 2021 we had 12.4~~2022:


	Number of Restricted Stock Awards	Weighted Average Fair Value per Share at Grant Date
Unvested at December 31, 2021	4,436,007	$	3.33
Granted	2,160,240	1.20
Vested	(1,804,526)	3.77
Forfeited	(875,513)	2.61
Unvested at September 30, 2022	3,916,208	$	2.11

The Company recorded stock-based compensation expense of $1.3 million ~~options outstanding with a weighted average exercise price of $5.87. Additionally, we granted 2.4~~and $4.2 million ~~restricted stock awards with a weighted average grant date fair value of $3.62 during~~for the three and nine months ended September 30, ~~2021. At~~2022, respectively, related to RSAs. As of September 30, ~~2021 we had 4.9~~2022, there was approximately $5.7 million of unrecognized compensation expense related to the unvested portions of RSAs, which is expected to be recognized over a weighted-average period of approximately 1.7 years. The expense for time-based vesting awards is recognized over the vesting period of the award.

The following table summarizes activity related to restricted stock ~~awards outstanding with~~units (“RSUs”) for the nine months ended September 30, 2022:


	Number of Restricted Stock Units	Weighted Average Fair Value per Share at Grant Date
Outstanding at December 31, 2021	184,512	$	23.53
Granted	1,677,552	0.71
Vested	—	—
Forfeited	(4,512)	—
Outstanding at September 30, 2022	1,857,552��	$	0.71

The Company recorded stock-based compensation expense of $0.1 million and $0.2 million for the three and nine months ended September 30, 2022, respectively, related to RSUs. As of September 30, 2022, there was approximately $1.2 million of unrecognized compensation expense related to the unvested portions of RSUs, which is expected to be recognized over a ~~weighted average grant date~~weighted-average period of approximately 2.3 years.

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2022:

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)


	Number of Shares	Weighted- Average Exercise Price/Share		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2021	9,505,461	$	6.42	5.86
Granted	6,885,316	0.68
Exercised	—	—			$	—
Forfeited	(181,914)	3.34
Expired	(1,239,985)	7.28
Outstanding at September 30, 2022	14,968,878	$	3.74	7.59	$	—
Vested and Expected to Vest at September 30, 2022	7,760,304	$	1.08	9.26	$	—
Exercisable at September 30, 2022	6,045,584	$	7.68	5.12	$	—

The Company recorded stock-based compensation expense of $0.8 million and $2.1 million for the three and nine months ended September 30, 2022, respectively, related to stock options. As of September 30, 2022, there was approximately $5.1 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.1 years.

The Company used the Black-Scholes option pricing model for determining the estimated fair value of ~~$4.70.~~stock-based compensation related to stock options. The table below summarizes the assumptions used:


	Nine Months Ended September 30,
	2022	2021
Expected life (in years)	5.57	5.50
Risk-free interest rate	1.70% - 3.30%	0.56% - 1.01%
Expected volatility	83.6% - 90.5%	80.0% - 81.3%
Expected dividend yield	—%	—%
Weighted-average grant-date fair value per stock option	$0.48	$2.42

Note 6.7. Financial Commitments and Contingencies and Key License Agreements

(a) Facility and Equipment Leases

Overview

In the ordinary course of our business, we enter into leases with unaffiliated parties for the use of (i) office and research facilities and (ii) office equipment. Our current leases have remaining terms ranging from ~~less than~~ ~~one~~two to ~~five~~four years and none include any residual value guarantees, restrictive covenants, term extensions, or early-termination options.

We lease our principal executive office in ~~Henderson, Nevada~~Boston, Massachusetts under a non-cancelable operating lease expiring ~~October~~December 31, ~~2021 which has been extended through October 31, 2022.~~2024. We also ~~lease~~leased our research and development facility, in addition to other administrative office leases, in Irvine, California under a non-cancelable operating lease which expired on July 31, 2022. In June 2022, we entered into a new office facility lease in Irvine, California under a non-cancelable operating lease expiring July 31, ~~2022, in addition to other administrative office leases.~~2025. We ~~entered into a new~~also leased an office facility ~~lease~~ in ~~Boston~~Henderson, Nevada under a non-cancelable operating lease ~~expiring in December~~which expired on October 31, ~~2024.~~2022. We recognize lease expense on a straight-line basis over the expected term of these operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations.

Our facility leases have minimum annual rents, payable monthly, and some carry fixed annual rent increases. Under some of these arrangements, real estate taxes, insurance, certain operating expenses, and common area maintenance are reimbursable to the lessor. These amounts are expensed as incurred, as they are variable in nature and therefore excluded from the

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

measurement of our reported lease asset and liability discussed below. As of September 30, ~~2021~~2022 and ~~2020,~~2021, we had no sublease arrangements with us as lessor, and no finance leases, as defined in ASU 2016-02, Leases (“Topic 842”).

The reported asset and liability, respectively, represents (i) the economic benefit of our use of leased facilities and equipment and (ii) the present-value of our contractual minimum lease payments, applying our estimated incremental borrowing rate as of the lease commencement date (since an implicit interest rate is not readily determinable in any of our leases). The recorded asset and liability associated with each lease is amortized over the respective lease term using the effective interest rate method. During the three and nine months ended September 30, ~~2021,~~2022, we recognized ~~$1.8~~$0.4 million of additional right-of-use assets in exchange for ~~$1.8 million~~ lease liabilities.

We elected to not separate “lease components” from “non-lease components” in our measurement of minimum payments for our facility leases and office equipment leases. Additionally, we elected to not recognize a lease asset and liability for a term of 12 months or less.

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

Financial Reporting Captions

The below table summarizes the lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets:

Operating Leases Condensed Consolidated Balance Sheet Caption September 30, 2021 December 31, 2020
Operating lease right-of-use assets - non-current Facility and equipment under lease $ 2,881 $ 2,247
Operating lease liabilities - current Accounts payable and other accrued liabilities 1,451 1,544
Operating lease liabilities - non-current Other long-term liabilities 1,593 883
Total operating lease liabilities $ 3,044 $ 2,427


Operating Leases	Condensed Consolidated Balance Sheet Caption	September 30, 2022		December 31, 2021
Operating lease right-of-use assets - non-current	Facility and equipment under lease	$	1,869	$	2,505

Operating lease liabilities - current	Accounts payable and other accrued liabilities	752		1,282
Operating lease liabilities - non-current	Other long-term liabilities	1,249		1,452
Total operating lease liabilities		$	2,001	$	2,734

As of September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, our “facility and equipment under lease” consisted of office and research facilities of ~~$2.5~~$1.5 million and ~~$1.9~~$2.1 million, respectively, and office equipment of $0.4 million and ~~$0.3~~$0.4 million, respectively.

Components of Lease Expense

We recognize lease expense on a straight-line basis over the term of our operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations. The components of our aggregate lease expense is summarized below:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Operating lease cost	Operating lease cost	$	381	$	466	$	1,274	$	1,398	Operating lease cost	$	266	$	381	$	1,109	$	1,274
Variable lease cost	Variable lease cost	79		86		280		314		Variable lease cost	38		79		236		280
Short-term lease cost	Short-term lease cost	13		17		46		46		Short-term lease cost	5		13		50		46
Total lease cost	Total lease cost	$	473	$	569	$	1,600	$	1,758	Total lease cost	$	309	$	473	$	1,395	$	1,600

Weighted Average Remaining Lease Term and Applied Discount Rate

Weighted Average Remaining Lease Term

Weighted Average Discount Rate

Operating leases as of September 30, ~~2021~~2022

2.7 years

~~4.2%~~3.0%

Operating leases as of December 31, ~~2020~~2021

~~1.6~~2.7 years

~~7.8%~~3.8%

Future Contractual Lease Payments

~~The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments:~~

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

Operating Leases - future payments September 30, 2021
2021 (remaining) $ 382
2022 1,301
2023 657
2024 669
2025 98
2026 73
Total future lease payments, undiscounted $ 3,180
(Less): Implied interest (136)
Present value of operating lease payments $ 3,044
The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments:


Operating Leases - future payments	September 30, 2022
2022 (remaining)	$	198
2023	804
2024	821
2025	188
2026 and thereafter	73
Total future lease payments, undiscounted	$	2,084
(Less): Implied interest	(83)
Present value of operating lease payments	$	2,001

(b) In/Out Licensing Agreements and Co-Development Arrangements

Overview

The in-license agreements for our development-stage drug products provide us with territory-specific rights to their manufacture and distribution (including further sub-licensing/out-licensing rights). We are generally responsible for all related clinical development costs, patent filings and maintenance costs, marketing costs, and liability insurance costs. We also may enter into out-license agreements for territory-specific rights to these drug products which include one or more of: upfront license fees, royalties from our licensees’ sales, and/or milestone payments from our licensees’ sales or regulatory achievements. For certain drug products, we may enter into cost-sharing arrangements with licensees and licensors.

We are also obligated to make specified milestone payments to our licensors upon the achievement of certain regulatory and sales milestones, and to pay royalties based on our net sales of all in-licensed products. Depending on the milestone achievement type and whether the product has been approved, we will either (a) capitalize the value to “intangible assets” in the Condensed Consolidated Balance Sheets or (b) recognize the payment value within “research and development” or “cost of sales” on the Condensed Consolidated Statements of Operations. The liability relating to the payment due to the licensor will be recognized in the earliest period that we determine the respective milestone achievement is probable or ~~occurs.~~has occurred.

~~Impact of Commercial Product Portfolio Transaction~~

In March 2019, we completed the Commercial Product Portfolio Transaction and substantially all of the contractual rights and obligations associated with the Commercial Product Portfolio were transferred to Acrotech at the closing of the Commercial Product Portfolio Transaction. However, under the terms of this transaction we retained our trade “accounts receivable, net” and GTN liabilities included within “accounts payable and other accrued liabilities” associated with our product sales made on and prior to February 28, 2019.

Accordingly, these Condensed Consolidated Financial Statements reflect the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations”. The most significant remaining agreements associated with our ~~continuing~~ operations, ~~are listed below,~~ along with the key financial terms and our corresponding accounting and reporting conventions for ~~each:~~each, are as follows:

(i) ~~ROLONTIS:~~ROLVEDON: Co-Development and Commercialization Agreement with Hanmi

In October 2014, we exercised our option under a License Option and Research Collaboration Agreement dated January 2012 (as amended) with Hanmi Pharmaceutical Co. ~~Ltd.~~, Ltd (“Hanmi”) for ~~ROLONTIS,~~ROLVEDON, a drug based on Hanmi’s proprietary LAPSCOVERY™ technology for the treatment of chemotherapy induced neutropenia. Under the terms of this agreement, as amended, we have primary financial responsibility for the ~~ROLONTIS~~ROLVEDON development plan and hold its worldwide rights (except for Korea, China, and Japan). We

Effective January 1, 2022, we executed an amendment to this license agreement, whereby we are contractually obligated to pay Hanmi ~~tiered royalties that range from the low double-digits to mid-teens~~a flat mid-single digit royalty on our aggregate annual net sales of ~~ROLONTIS.~~

WeROLVEDON. Additionally, Hanmi has agreed to release the Company from a prior purchase obligation for ROLVEDON drug substance which resulted in a reduction in accrued liabilities of $11.2 million with a corresponding reduction in research and development expense. In addition, beginning in year three after the commercial launch, we are responsible for ~~regulatory milestone~~a supplemental mid-single digit royalty on aggregate annual net sales. This supplemental royalty will terminate once the aggregate payments made to Hanmi meet the milestone limit of ~~$10~~$10.0 million, ~~upon approval of ROLONTIS, and sales milestone payments of up to $120 million per calendar year~~ based on ~~our annual net sales~~the supplemental royalty. For the three and nine months ended September 30, 2022, we have a $9 million obligation to Hanmi related to the purchase of ~~ROLONTIS.~~inventory.

(ii) Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

~~(ii) Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson~~

In February 2015, we executed ~~an in-license~~a co-development and commercialization agreement with Hanmi for poziotinib, a pan-HER inhibitor in Phase 2 clinical trials, (which has also shown single agent activity in the treatment of various cancer types during Phase 1 studies, including breast, gastric, colorectal, and lung cancers) and made an upfront payment to Hanmi for these distribution rights.

Under the terms of this agreement, we received the exclusive global rights to commercialize poziotinib, except for Korea and China. Hanmi and its development partners are fully responsible for the completion of on-going Phase 2 trials in Korea. We are financially responsible for all other clinical studies. ~~We are obligated~~

Effective January 1, 2022, we executed an amendment to ~~make contractual~~this in-license agreement, whereby the payments to Hanmi upon our achievement of various regulatory milestones ~~that~~now aggregate to ~~$33 million. We are also obligated to pay Hanmi~~$18.0 million, which includes eliminating the first approval milestone payment in return for a supplemental mid-single digit royalty on aggregate annual net sales ~~milestones~~beginning in year three after the commercial launch. This supplemental royalty will terminate once the aggregate payments made to Hanmi meet the milestone limit of up$15.0 million, based on the supplemental royalty. There were no contractual obligations to ~~$325 million annually and pay royalties in~~Hanmi under the ~~low to mid-teen digits on our net sales of poziotinib, potentially reduced by royalties due to other third parties.~~previous agreement for the three or nine months ended September 30, 2022.

In April 2018, we executed an exclusive patent and technology agreement for the use of poziotinib in treating patients with EGFR and HER2 exon 20 mutations in cancer and HER2 exon 19 mutations in cancer with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). MD Anderson discovered poziotinib’s use in treating these patient-types. We made an upfront payment to MD Anderson of $0.5 million upon the execution of this agreement.

We are contractually obligated to pay nominal fixed annual license maintenance fees to MD Anderson and pay additional fees upon our achievement of various regulatory and sales milestones. These regulatory milestones aggregate $6to $6.0 million and the sales milestones aggregate ~~$24~~to $24.0 million. We are also contractually obligated to pay MD Anderson royalties in the low single-digits on our net sales of poziotinib.

(iii) In-License Agreement with ImmunGene for FIT Drug Delivery Platform

In April 2019, we executed an asset transfer, license, and sublicense agreement with ImmunGene, Inc. (“ImmunGene”) for an exclusive license for the intellectual property related to (a) Anti-CD20-IFNα, an antibody-interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma patients, representing a considerable unmet medical need, and (b) an antibody-interferon fusion molecule directed against GRP94, a target for which currently there are no existing approved therapies that have the potential for treating both solid and hematologic malignancies. Both molecules are based on the Focused Interferon Therapeutics (“FIT”) drug delivery platform.

~~We made upfront payments aggregating $2.8 million~~In November 2021, we provided notice to terminate the asset transfer, license, and sublicense agreement with ImmunGene, Inc. Pursuant to the agreement, we will transfer the rights, title or interest with respect to the transferred product back to ImmunGene. There were no contractual obligations to ImmunGene for the three or nine months ended September 30, 2022.

As of September 30, 2022 we are no longer prosecuting or maintaining any ImmunGene intellectual property and to several other third parties. We will make further payments to ImmunGene upon our achievement of various regulatory milestones that aggregate to $26.1 million, plus an additional $5 million milestone payment for each new indication (beyond those described above) approved for either drug in the U.S., Europe, or Japan.

~~Our contractual royalties to ImmunGene~~we are ~~in the high-single digits on our net sales of each drug, potentially reduced by our royalties due to other third parties. We are also~~not contractually obligated to pay nominal fixed annual license maintenance fees to ~~2 licensors.~~any ImmunGene-related licensor.

(iv) In-License Agreement with Therapyx

In December 2020, we executed an asset transfer and license agreement with Therapyx, Inc. (“Therapyx”) for an exclusive worldwide license for the intellectual property related to any pharmaceutical or biological product for use in human oncology containing, whether as its sole active or in combination with other active ingredients, an encapsulated IL-12, in any injectable dosage form or formulation.

We made an upfront payment of $0.8 million to Therapyx upon contract execution, which was recorded to “research and development” expense within our Consolidated Statements of Operations for the year ended December 31, 2020. We will make an additional payment of $2.2 million upon our acceptance of certain transferred materials from Therapyx. We will make further payments to Therapyx upon our achievement of various (i) regulatory milestones aggregating up to $30 million for the first approved IL-12 product, plus an additional $2.5 million milestone payment for each new indication approved for each product in the U.S., Europe, or Japan; and (ii) sales milestones aggregating up to $167.5 million based on worldwide annual net sales. We are contractually obligated to pay royalties in the mid-single digits on our net sales of all IL-12 products, potentially reduced by royalties due to third parties, the loss of IP protection within one or more countries, or the introduction of a competing product within one or more countries.

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

~~reduced by royalties due to third parties, the loss of IP protection within one or more countries, or the introduction of a competing product within one or more countries.~~

Depending on the nature of the milestone achievement type we will either (a) capitalize the payment value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the payment value within “research and development” or “cost of sales” within the Consolidated Statements of Operations. The corresponding liability for the payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or ~~occurs.~~has occurred.

We have entered into various contracts with numerous third-party service providers for the execution of our research and development initiatives. These vendors include raw material suppliers, clinical trial sites, clinical research organizations, and data monitoring centers, among others. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on the achievement of certain events specified in the agreements - such as contract execution, progress of service completion, delivery of drug supply, and the dosing of patients in clinical studies.

We recognize these “research and development” expenses and corresponding “accounts payable and other accrued liabilities” in the accompanying financial statements based on estimates of our vendors’ progress of performed services, patient enrollments and dosing, completion of clinical studies, and other events. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would typically be limited to the extent of the work completed, as we are generally able to terminate these contracts with adequate notice.

(d) Supply and Service Agreements Associated with Product Production

We have various product supply agreements and/or have issued vendor purchase orders that obligate us to agreed-upon raw material purchases from certain vendors. We also have certain drug production service agreements with select contract manufacturers that obligate us to service fees during the contractual period. ~~These collective commitments do not exceed our planned commercial requirements; the corresponding contracted prices do not exceed their current fair market values.~~

(e) Employment Agreements

We entered into revised employment agreements with ~~each~~certain of our named executive officers (chief executive ~~officer, chief operating officer, chief financial~~ officer, chief legal officer, and chief medical officer) in April/June 2018 and June 2019, which supersede any prior change in control severance agreements with such individuals. Also, we entered into an employment agreement with our current chief financial officer in April 2022. These agreements provide for the payment of certain benefits to each executive upon ~~his~~their separation of employment under specified circumstances. These arrangements are designed to encourage each to act in the best interests of our stockholders at all times during the course of a change in control event or other significant transaction.

We previously entered into an employment agreement with our former Chief Executive Officer, Joseph Turgeon, under which cash compensation and benefits would become payable in the event of termination by us for any reason other than cause, his resignation for good reason, or upon a change in control of our Company. Effective December 31, 2021, Mr. Turgeon’s employment with the Company was terminated without cause in accordance with his employment agreement. We have accrued $2.6 million and $3.1 million for all contractual amounts due and unpaid to Mr. Turgeon as of September 30, 2022 and December 31, 2021, respectively, within "accrued payroll and benefits" on the accompanying Consolidated Balance Sheets.

(f) Deferred Compensation Plan

The Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”) is ~~administered~~governed by ~~the~~our Compensation Committee ~~of our Board of Directors~~ and is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended.

The DC Plan is maintained to provide special deferred benefits for a select group of our employees (the “DC Participants”). DC Participants make annual elections to defer a portion of their eligible cash compensation which is then placed into their DC Plan accounts. We match a fixed percentage of these deferrals, and may make additional discretionary contributions. At September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the aggregate value of this DC Plan liability was ~~$10.5~~$7.4 million and ~~$9.8~~$11.2 million, respectively, and is included within “accounts payable and other accrued liabilities” and “other long-term liabilities” in the accompanying Condensed Consolidated Balance Sheets.

(g) Litigation

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims. We may also be subject to derivative lawsuits from time to time.

We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are assessed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.

Bioverativ Patent Litigation

On May 28, 2021, Bioverativ Therapeutics Inc. (“Bioverativ”) filed a complaint against us in the U.S. District Court for the District of Delaware, which alleges that our proposed manufacture, use and sale of ~~ROLONTIS~~eflapegrastim (now known as ROLVEDON) would, if approved, infringe claims of 3three patents owned by Bioverativ (the “Subject Patents”). Bioverativ ~~is seeking~~sought an unspecified amount of damages and injunctive relief.

We believe that our manufacture, use and sale of ROLONTIS would not infringe the Subject Patents and intend to vigorously defend our right to develop and commercialize ROLONTIS in accordance with the terms of our agreements with Hanmi.

Pursuant to our agreements with Hanmi, we hold worldwide rights (except for Korea, China, and Japan) to develop and commercialize ~~ROLONTIS.~~eflapegrastim. The agreements with Hanmi contain typical license terms including, without limitation, indemnification rights in favor of the Company with respect to any claims of infringement from a third party with respect to our use of a licensed technology, product or compound pursuant to such agreements.

Related to the Bioverativ litigation, on December 20, 2021, we were named as respondents in an International Trade Commission (“ITC”) action filed with the ITC. The complaint alleged importation into the United States, the sale for importation, and the sale within the United States after importation of certain monomer-dimer hybrid immunoconjugates in violation of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337).

~~Shareholder Litigation~~On February 18, 2022, Spectrum, Hanmi and Bioverativ entered into a license and settlement agreement which included a stipulation to dismiss the Bioverativ litigation and withdraw the ITC complaint. On February 18, 2022, the ITC action against us was withdrawn, and on March 2, 2022, the Bioverativ case was dismissed by the U.S. District Court.

Luo v. Spectrum Pharmaceuticals, Inc., et al.

On August 31, 2021, a shareholder lawsuit was filed against us in the U.S. District Court for the District of Nevada, which alleges that we and certain of our executive officers made false or misleading statements and failed to disclose material facts about our business and the prospects of approval for our BLA to the FDA for ~~ROLONTIS~~eflapegrastim in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Securities Exchange Act of 1934, as amended. On November 1, 2021, 4four individuals and 1one entity filed competing motions to be appointed lead plaintiff and for approval of counsel in this putative securities class action. The plaintiffs seek damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. On March 2, 2022, the Court entered an order partially granting and partially denying without prejudice a stipulated order eliminating defendants’ obligation to answer the initial pleading pending an amended complaint and addressing related briefing scheduling for an anticipated motion to dismiss. On July 28, 2022, the Court appointed a lead plaintiff and counsel for the class. On September 26, 2022, an amended complaint was filed alleging misleading statements with respect to ROLONTIS manufacturing operations and controls and added allegations that defendants misled investors about the efficacy of and market need for Poziotinib between the Class Period of March 7, 2018 and August 5, 2021. We believe that these claims are without merit and intend to vigorously defend against these claims.

Csaba v. Turgeon, et. al, (filed December 15, 2021 in the U.S. District Court District of Nevada); Shumacher v. Turgeon, et. al, (filed March 15, 2022 in the U.S. District Court District of Nevada); Johnson v. Turgeon, et. al, (filed March 29, 2022 in the U.S. District Court District of Nevada); Raul v. Turgeon, et. al, (filed April 28, 2022 in the U.S. District of Delaware); and Albayrak v. Turgeon, et al, (filed June 9, 2022 in the U.S. District Court District of Nevada). These putative stockholder derivative actions were filed against us(as a nominal defendant), certain of our executive officers, and certain of our past and present members of the board of directors. The stockholder derivative complaints allege that certain of our executive officers are liable to Spectrum, pursuant to Section 10(b) and 21(d) of the Securities Exchange Act of 1934, as amended, for contribution and indemnification, if they are deemed (in the Luo class action), to have made false or misleading statements and failed to disclose material facts about our business and the prospects of approval for our BLA to the FDA for eflapegrastim. The complaints generally but not uniformly further allege that certain of our executive officers and certain of our past and present directors breached their fiduciary duties, and certain of our present directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about our

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

business and the prospects of approval for our BLA to the FDA for eflapegrastim. The allegations state that as a result of the violations, certain of our executive officers and past and present board members committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief.

The parties are in the process of seeking court approval for the consolidation of the Nevada derivative actions and staying all derivative actions until there is an adverse decision on a motion to dismiss in the Nevada securities class action. We believe that these claims are without merit and intend to vigorously defend against these claims.

Note 7.8. Discontinued Operations

Overview

In March 2019, we completed the sale of our seven then-commercialized drugs (the “Commercial Product Portfolio”) to Acrotech in the Commercial Product Portfolio Transaction. ~~In accordance~~Upon closing we received $158.8 million in an upfront cash payment. We are also entitled to receive up to an aggregate of $140 million upon Acrotech’s future achievement of certain regulatory milestones (totaling $40 million) and sales-based milestones (totaling $100 million) relating to the Commercial Product Portfolio.

Substantially all of the contractual rights and obligations associated with ~~applicable GAAP (ASC 205-20, Presentation~~the Commercial Product Portfolio were transferred to Acrotech at the closing of the Commercial Product Portfolio Transaction. However, under the terms of this transaction we retained our trade “accounts receivable, net” and GTN liabilities included within “accounts payable and other accrued liabilities” associated with our product sales made on and prior to February 28, 2019. Accordingly, these Condensed Consolidated Financial Statements), reflect the corresponding revenue-deriving activities and allocable expenses of ~~our sold~~this commercial ~~operation, connected to the Commercial Product Portfolio, are separately classified as “discontinued” for all periods presented~~business within ~~the accompanying Condensed Consolidated Statements of Operations.~~“discontinued operations.”

Condensed Consolidated Statements of Operations

The following table presents the various elements of ~~“income (loss)~~“loss from discontinued operations, net of income taxes” as reported in the accompanying Condensed Consolidated Statements of Operations:

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Revenues:
Product sales, net $ — $ (1) $ — $ (101)
Total revenues — (1) — (101)
Operating costs and expenses:
Cost of sales (excluding amortization of intangible assets) 6 — 133 (229)
Selling, general and administrative — — — (1)
Research and development 5 (67) 94 (126)
Total operating costs and expenses 11 (67) 227 (356)
Income (loss) from discontinued operations before income taxes (11) 66 (227) 255
Provision for income taxes from discontinued operations — — — —
Income (loss) from discontinued operations, net of income taxes $ (11) $ 66 $ (227) $ 255

~~Condensed Consolidated Balance Sheets~~

Accounts receivable derived from our product sales on and prior to February 28, 2019 were not transferred to Acrotech as part of Commercial Product Portfolio Transaction, nor were our GTN liabilities and trade accounts payable assumed by Acrotech that were associated with our commercial activities on and prior to February 28, 2019. Accordingly, these specific assets and liabilities remain presented within “accounts receivable, net and “accounts payable and other accrued liabilities” on the accompanying Condensed Consolidated Balance Sheets.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenues:
Product sales, net	$	—	$	—	$	39	$	—

Total revenues	—		—		39		—
Operating costs and expenses:
Cost of sales (excluding amortization of intangible assets)	3		6		47		133
Selling, general and administrative	—		—		—		—
Research and development	(7)		5		31		94


Total operating costs and expenses	(4)		11		78		227





Income (loss) from discontinued operations before income taxes	4		(11)		(39)		(227)
Provision for income taxes from discontinued operations	—		—		—		—
Income (loss) from discontinued operations, net of income taxes	$	4	$	(11)	$	(39)	$	(227)

Note 8.9. Stockholders’ Equity

Sale of Common Stock Under ATM Agreement

On April 5, 2019, we entered into a collective at-the-market-issuance (“ATM”) sales agreement with Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC and B. Riley FBR, Inc. (the “April 2019 ATM Agreement”), pursuant to which we may offer and sell shares of our common stock by any method deemed to be an “at the market” offering (the “ATM Offering”). From April 5, 2019 to March 2, 2020, the ATM Offering was conducted pursuant to a sales agreement prospectus filed with our automatic shelf registration statement on Form S-3ASR, filed with the SEC on April 5, 2019, which registered an aggregate

Table of Contents

Notes to Condensed Consolidated Financial Statements

(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)

(Unaudited)

offering price of $150 million under the April 2019 ATM Agreement. From May 8, 2020 to June 30, 2020, the ATM Offering was conducted pursuant to a sales agreement prospectus (the “Initial Sales Agreement Prospectus”) filed with our shelf registration statement on Form S-3, filed with the SEC on March 20, 2020, as amended by Pre-Effective Amendment No. 1 thereto, and declared effective by the SEC on May 8, 2020 (the “Registration Statement”), which registered an aggregate offering price of up to $75 million under the April 2019 ATM Agreement. On July 29, 2020, we terminated the Initial Sales Agreement Prospectus, but left the April 2019 ATM Agreement in full force and effect. On November 6, 2020, we filed a new sales agreement prospectus to the Registration Statement, which registered an aggregate offering price of up to $60 million under the April 2019 ATM Agreement.

On July 13, 2021, we filed a shelf registration statement with the SEC on Form S-3, which was declared effective by the SEC on July 21, 2021 (the “Registration Statement”). The Registration Statement registered an aggregate offering price of up to $300 million of securities that may be issued and sold by us from time to time, including up to an aggregate offering price of $150 million of common stock (which amount is included in the $300 million aggregate offering price set forth in the base prospectus) that may be issued and sold pursuant to the April 2019 ATM Agreement.

During January 2022, the Company entered into a Securities Purchase Agreement with Hanmi, pursuant to which Hanmi purchased 12,500,000 shares of our common shares at a purchase price of $1.60 per share, for an aggregate purchase price equal to $20 million.

We sold and issued common shares under the April 2019 ATM Agreement as follows:

~~Table of Contents~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(all tabular amounts presented in thousands, except share, per share, interest rate, and number of years)~~

~~(Unaudited)~~

Period in Which Issued No. of Common Shares Issued Proceeds Received
(Net of Broker Commissions and Fees )
Year ended December 31, 2019 221,529 $ 1,814
Year ended December 31, 2020 3,950,398 $ 14,902
Quarter ended March 31, 2021 5,678,893 $ 21,357
Quarter ended June 30, 2021 10,172,498 $ 31,265
Quarter ended September 30, 2021 — $ —


Period in Which Issued	No. of Common Shares Issued	Proceeds Received (Net of Broker Commissions and Fees )

Year ended December 31, 2021	15,851,391	$	52,621
Quarter ended June 30, 2022	5,619,827	$	4,947
Quarter ended September 30, 2022	18,894,118	$	21,613

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our future product development and commercialization activities and costs, the revenue potential (licensing, royalty and sales) of our products and product candidates, the impact of the ~~novel~~ongoing resurgences in coronavirus (“COVID-19”) ~~global pandemic~~infections or new strains of the virus on our business, the success, safety and efficacy of our drug products, revenues and revenue assumptions, clinical studies, including designs and implementation, development and commercialization timelines, product acquisitions, accounting principles, litigation expenses, liquidity and capital resources and trends, and other statements containing forward-looking words, such as, “believes,” “may,” “could,” “would,” “will,” “expects,” “intends,” “estimates,” “anticipates,” “plans,” “seeks,” “continues,” or the negative thereof or variation thereon or similar terminology (although not all forward-looking statements contain these words). Such forward-looking statements are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. All forward-looking statements included in this Form 10-Q speak only as of the date of this Form 10-Q and readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in our periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020,~~2021, as well as those discussed elsewhere in this Quarterly Report on Form 10-Q, and the following factors, among others:

•our ability to successfully develop, obtain regulatory approval of, and market our products;

•the approval, or timing of approval, of our products or new indications for our products by the U.S. Food and Drug Administration (the “FDA”) and other international regulatory agencies;

•the overall impact of COVID-19 on our business, including, without limitation, delays caused by COVID-19 related travel restrictions;

•actions by the FDA and other regulatory agencies, including international agencies;

•the timing and/or results of pending or future clinical trials, and our reliance on contract research organizations;

•our ability to maintain sufficient cash resources to fund our business operations;

•our history of net losses;

•our ability to enter into strategic alliances with partners for manufacturing, development and commercialization;

•our competitors’ progress with their drug development programs, which could adversely impact the perceived or actual value of our in-development drugs;

•our dependence on the production capabilities of contract manufacturing organizations (“CMOs”) and other third-parties for active pharmaceutical ingredients (“APIs”), drug products, related supplies and logistical services;

•the ability of our manufacturing partners to satisfy regulatory requirements and to meet our product demands and timelines;

•our ability to identify and acquire new product candidates and to successfully integrate those product candidates into our operations;

•our ability to protect our intellectual property rights;

•the impact of legislative or regulatory reform on the pricing for pharmaceutical products;

•the impact of any litigation to which we are, or may become a ~~party, including, without limitation, the patent infringement claims made against us by Bioverativ Therapeutics, Inc.;~~party;

~~Table of~~ ~~Contents~~

•our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and

Table of Contents

•our ability to maintain the services of our key executives and other personnel.

All subsequent written and oral forward-looking statements attributable to us or by persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. We expressly disclaim any intent or obligation to update information contained in any forward-looking statement after the date thereof to conform such information to actual results or to changes in our opinions or expectations.

Impact of COVID-19 Pandemic

On March 11, 2020, COVID-19 was declared a pandemic by the World Health Organization. Concerns related to the spread of COVID-19 have created global business disruptions as well as disruptions in our operations. The ongoing COVID-19 pandemic has adversely impacted economic activity and conditions worldwide, including workforces, liquidity, capital markets, consumer behavior, supply chains, and macroeconomic conditions. ~~Notably, a new Delta variant of COVID-19, which appears to be the most transmissible variant to date, has begun to spread globally. The impact of the Delta variant~~Despite progress in vaccination efforts, global economic activity remains uncertain and cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19 vaccines against the Delta variant and the response by governmental bodies and regulators.

~~On October 26, 2020, we announced that the~~ ~~FDA~~ ~~had deferred action on our Biologics License Application (“BLA”)~~ for ROLONTIS due to the inability to conduct an inspection of the Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) third-party manufacturing facility in South Korea as a result of COVID-19 related travel restrictions. In early June 2021, the FDA conducted the pre-approval inspection of the Hanmi manufacturing facility. In August 2021, we received a Complete Response Letter from the FDA regarding our BLA, citing deficiencies related to manufacturing and indicating that a reinspection will be necessary. We are seeking further clarification from the FDA and plan to meet with ~~the agency as soon as possible.~~

confidence.

The extent to which the COVID-19 pandemic may continue to impact our results of operations, including the long-term nature of the impacts, depends on numerous evolving factors, which are highly uncertain and difficult to predict, including the adoption rate of the COVID-19 vaccines, the emergence and spread of variants, ~~(including the Delta variant, a rapidly spreading strain of coronavirus),~~ the scope and the timing to further contain the virus or treat its impact, and to what extent normal economic and operating conditions can resume, among others. For more information related to the impact of COVID-19 on our business, refer to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, as filed with the SEC on March ~~31, 2021, and in our Quarterly Report on Form 10-Q for the period ended June 30, 2021, as filed with the SEC on August 12, 2021.~~17, 2022.

Company Overview

Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biopharmaceutical company, with a primary strategy comprised of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house development organization includes clinical development, regulatory, quality, data management and ~~data management. We continue to build out our commercial and marketing capabilities to prepare for the launch of ROLONTIS.~~commercialization.

We have ~~three drugs~~one commercial asset and one drug in late-stage development:

•~~ROLONTIS,~~ROLVEDON, a novel long-acting granulocyte colony-stimulating factor (“G-CSF”) for the treatment of chemotherapy-induced neutropenia. ~~We submitted a BLA for ROLONTIS in December 2019,~~On April 11, 2022, the Company announced that it had received notice that the Biologics License Application (“BLA”) had been accepted and ~~in August 2021 we~~ received a ~~Complete Response Letter from~~Prescription Drug User Fee Act (“PDUFA”) date of September 9, 2022. On September 9, 2022, the Company received FDA ~~regarding our BLA, citing deficiencies related to manufacturing~~marketing approval for ROLVEDON; and indicating that a reinspection will be necessary. We are currently working on remediating the manufacturing deficiencies and expect that this work will be complete in the fourth quarter of 2021 and plan to resubmit thereafter;

•Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations. AOn December 6, 2021, the Company announced it submitted its New Drug Application (“NDA”) ~~based on data from Cohort 2 of ZENITH20, which evaluated~~for poziotinib to the FDA for use in patients with previously treated ~~patients with~~locally advanced or metastatic NSCLC with HER2 exon 20 insertion ~~mutation~~mutations. The NDA submission is ~~expected to be filed~~based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. The product has received Fast Track designation and there is currently no treatment specifically approved by the FDA for this indication. On February 11, 2022, the Company announced that it had received notice that the NDA had been accepted and received a PDUFA action date of November 24, 2022. On September 22, 2022, the Company met with the ~~FDA in 2021; and~~

•~~Anti-CD20-IFNα, an antibody-interferon fusion molecule directed against CD20~~FDA’s Oncologic Drugs Advisory Committee (“ODAC”). ODAC voted 9-4 that ~~is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma patients.~~

~~Table~~the current benefits of ~~Contents~~poziotinib did not outweigh its risks.

Our business strategy is the development of our late-stage assets through commercialization and the sourcing of additional assets that are synergistic with our existing portfolio (through purchase acquisitions, in-licensing transactions, or co-development and marketing arrangements).

Recent Highlights of Our Business, Product Development Initiatives, and Regulatory Approvals

Our product and commercial product pipeline is summarized below:

~~ROLONTIS,~~ROLVEDON, a novel long-acting G-CSF:

We submitted our ~~updated~~ BLA for ~~ROLONTIS~~ROLVEDON to the FDA on October 24, 2019 ~~which was accepted for review by the FDA on December 20, 2019. Our BLA~~that is supported by data from two similarly designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ~~ROLONTIS~~ROLVEDON in 643 early-stage breast cancer patients for the treatment of neutropenia due to myelosuppressive chemotherapy. Both studies met the

Table of Contents

pre-specified endpoint of non-inferiority in duration of severe neutropenia and met all of the secondary endpoints. In addition, the safety profile was similar to pegfilgrastim. On ~~October 26, 2020,~~August 6, 2021, we announced ~~that~~ the ~~FDA PDUFA target action date set for October 24, 2020 was deferred pending inspection~~receipt of the Hanmi manufacturing facility in Korea due to COVID-19 related travel restrictions. In early June 2021, the FDA conducted the pre-approval inspection of the Hanmi manufacturing facility. In August 2021, we received a Complete Response Letter ~~from the FDA regarding our BLA, citing deficiencies related to manufacturing and indicating that a reinspection will be necessary. We are currently working~~(“CRL”) based on ~~remediating the~~ manufacturing deficiencies identified at both the drug substance and ~~expect~~drug product manufacturers. The Company believes these manufacturing deficiencies have been remediated and on March 11, 2022, we resubmitted the BLA for ROLVEDON. On April 11, 2022, the Company announced that ~~this work will be complete~~it had received notice that the BLA had been accepted and received a PDUFA date of September 9, 2022. On September 9, 2022, the Company received FDA marketing approval for ROLVEDON injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ROLVEDON is currently being marketed for sale in the ~~fourth quarter of 2021 and plan to resubmit thereafter.~~United States.

A company sponsored clinical trial has been initiated to evaluate the administration of ~~ROLONTIS~~ROLVEDON on the same day as chemotherapy. This Phase 1 clinical trial is a randomized, open label, actively controlled study to evaluate the same-day dosing of ~~eflapegrastim~~ROLVEDON on duration of neutropenia when administered at varying intervals following docetaxel and cyclophosphamide (TC) chemotherapy in patients with early-stage breast cancer. On March 4, 2021, at the virtual 38th Annual Miami Breast Cancer Conference®, the ~~company~~Company presented positive early data showing rapid absolute neutrophil count (ANC) recovery in the first three patients dosed in the 30-minute arm of the same-day dosing. This arm met the prespecified interim safety evaluation criteria and therefore ~~supports~~supported the expansion of this arm to 15 patients. The study design included an interim safety evaluation that was conducted once the first three patients in each arm (30 minutes, 3 hours, or 5 hours) completed Cycle 1. Based on this review, the 30-minute arm ~~will expand~~expanded to a total of 15 patients, while the 3- and 5-hour dosing arms have been discontinued. In the 30-minute dosing arm, ANC recovery was more rapid compared to the 3- and 5-hour arms. The overall safety profile for the 30-minute arm was similar to what has been seen previously in large randomized studies with ~~GCSF~~G-CSF given 24 hours after chemotherapy.

Poziotinib, ~~an irreversible~~a Pan ErbB inhibitor targeting HER2 exon20 mutations:

Poziotinib is a novel, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (“EGFR”) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. This, in turn, leads to the inhibition of the proliferation of tumor cells that over-express these receptors. Mutations of over-expression/amplification of EGFR family receptors have been associated with a number of different cancers, including NSCLC, breast cancer, and gastric cancer. In February 2015, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Co., Ltd. (“Hanmi”) for poziotinib worldwide rights, except in Korea and China.

Our clinical development program for poziotinib is focused on previously treated NSCLC, first-line treatment of NSCLC and treatment of other solid tumors with HER2 mutations. NSCLC tumors with HER2 exon 20 insertion mutations are rare and have generally not been responsive to other tyrosine kinase ~~inhibitor targeting EGFR~~inhibitors. Patients with these mutations have a poor prognosis, and available treatment options are limited. Poziotinib, due to its unique chemical structure and characteristics, is believed to inhibit cell growth of tumors with HER2 ~~mutations:~~exon-20 insertion mutations.

In October 2017, we announced the start of our pivotal ZENITH20 Phase 2 global clinical trial with active sites in the U.S., Canada and Europe. The ZENITH20 trial ~~consists~~consisted of seven cohorts of NSCLC patients. Cohorts 1, 2, 3 and 4 have completed enrollment while Cohort 5 is continuing to enroll patients. We have closed Cohorts 6 and 7 for enrollment. Cohorts 1 (EGFR) and 2 (HER2) include previously treated NSCLC patients with exon 20 mutations. Cohort 3 (EGFR) and 4 (HER2) include first-line NSCLC patients with exon 20 mutations. Cohorts 1- 4 are each independently powered for a pre-specified statistical hypothesis and the primary endpoint is overall response rate (“ORR”). Cohort 5 includes previously treated ~~or treatment-naïve~~ NSCLC patients with ~~EGFR or~~ HER2 exon 20 insertion ~~mutations.~~mutations and is evaluating different dosing regimens. Cohort 6 ~~includes~~included NSCLC patients with classical EGFR mutations who progressed while on treatment with first-line osimertinib and developed an additional EGFR mutation. Cohort 7 ~~includes~~included NSCLC patients with a variety of less common mutations in EGFR or HER2 exons 18-21 or the extracellular or transmembrane domains. ~~Cohorts 1-3 have completed enrollment while Cohorts 4-7 continue to enroll patients.~~

On December 26, 2019, we announced that the pre-specified primary endpoint was not met in Cohort 1 of the ZENITH20 trial evaluating poziotinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations. Cohort 1 enrolled a total of 115 patients who received 16 mg/day of poziotinib. The intent-to-treat analysis showed that 17 patients had a response (by RECIST) and 62 patients had stable disease for a 68.7% disease control rate (“DCR”). The confirmed ORR was 14.8% (95% CI 8.9%-22.6%). The median duration of response was 7.4 months and the progression free survival was 4.2 months. The safety profile was in-line with other second-generation EGFR tyrosine kinase inhibitors.

On July 27, 2020, we announced that we met the pre-specified primary endpoint for Cohort 2 in the ZENITH20 trial evaluating previously treated NSCLC patients with HER2 exon 20 insertion mutations. Cohort 2 enrolled a total of 90 patients who received an oral, once daily dose of 16 mg of poziotinib. All the patients had failed at least one line of prior systemic therapy with 60 patients (67%) having failed two or more prior therapies, including chemotherapy and immunotherapy. All

Table of Contents

responses were read independently and confirmed by a central imaging laboratory using RECIST criteria. The intent-to-treat analysis demonstrated a confirmed ORR of 27.8% (95% CI of 18.9%-38.2%). Based on the pre-specified statistical hypothesis

~~Table of~~ ~~Contents~~

for the primary endpoint, the observed lower bound of 18.9% exceeded the pre-specified lower bound of 17% in this heavily pre-treated population. The safety profile was in-line with the type of adverse events seen with other second-generation EGFR tyrosine kinase inhibitors. These results were presented at the European Society for Medical Oncology (“ESMO”) Virtual Congress 2020 Science Weekend held in September 2020.

In March 2021, we announced that the FDA granted Fast Track designation for poziotinib based on data from Cohort 2 of ZENITH20, which evaluated previously treated patients with NSCLC with HER2 exon 20 insertion mutations. In December 2020, we reported that its pre-specified primary endpoint in Cohort 3 evaluating poziotinib in first-line NSCLC patients with EGFR exon 20 insertion mutations was not met. We additionally reported that preliminary data from patients receiving 8 mg of poziotinib twice daily demonstrated meaningful improvement in tolerability as measured by adverse events and dosing interruptions.

Cohort 3 of the ZENITH20 clinical trial enrolled a total of 79 patients who received an oral once daily dose of 16 mg of poziotinib. The median time of follow up of all patients was 9.2 months with 12 ongoing patients still on treatment. The intent-to-treat analysis showed that 22 patients had a partial response (by RECIST) and 68 patients had stable disease for an 86.1% DCR. 91% of patients experienced tumor reduction with a median reduction of 25.5%. The confirmed ORR was 27.8% (95% CI 18.4-39.1%). Based on the pre-specified statistical hypothesis for the primary endpoint, the observed lower bound of 18.4% did not meet the pre-specified lower bound of >20%. The median duration of response was 6.5 months and the median progression free survival was 7.2 months. The safety profile was similar with the type of adverse events observed with other second-generation EGFR tyrosine kinase inhibitors. Grade 3 treatment related rash was 33% and diarrhea was 23%. 94% of patients had drug interruptions with 6 patients (8%) permanently discontinuing due to adverse events.

In ~~April~~March 2021, ~~new~~we announced that the FDA granted Fast Track designation for poziotinib based on data ~~was presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021~~ from Cohort 2 of ZENITH20, ~~Cohort 5~~ which ~~demonstrated improved efficacy and tolerability for twice daily dosing. In the 38~~evaluated previously treated patients ~~comprised of EGFR or~~with NSCLC with HER2 exon 20 insertion ~~mutations, who received 16 mg per day and randomized either to~~mutations. On December 6, 2021, the Company announced the submission of its NDA for poziotinib 16 mg once daily or 8 mg twice daily in Cohort 5, improved responses were observed in the twice daily arm with 31.6% of patients reaching a partial response, while Grade 3 or higher adverse events were reduced by approximately 60%. Additionally, the twice daily dosing allowed for an improved rate of dose reductions and interruptions relative to the ~~once daily dose.~~

FDA for use in patients with previously treated locally advanced or metastatic NSCLC with HER2 exon 20 insertion mutations. The NDA submission is based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. On February 11, 2022, the Company announced that the file had been accepted and an action date of November 24, 2022 had been set.

In ~~September 2021, new data was~~March 2022, the Company presented the results of Cohort 4 at the European Society for Medical Oncology Targeted Anticancer Therapies (“ESMO ~~meeting that took place in Paris.~~TAT”) meeting. Cohort 4 of the ZENITH20 clinical trial ~~is enrolling treatment-naïve NSCLC~~enrolled a total of 70 patients, ~~with HER2 exon 20 insertion mutations. This cohort is investigating the efficacy~~48 of whom received an oral once daily dose of 16 mg of poziotinib ~~with a once daily (“QD”)~~ and 22 of who received an oral twice daily ~~(“BID”~~dose of 8 mg of poziotinib. The intent-to-treat analysis demonstrated a confirmed ORR of 41% (95% CI of 30%-54%) ~~(ongoing) dosing strategy. Poziotinib 16mg was administered orally once daily~~. Based on the pre-specified statistical hypothesis for the ~~first 48 patients allowing dose reductions/interruptions for toxicity. For these first 48 patients that were dosed at~~primary endpoint, the ~~16mg once per day dose,~~observed lower bound of 30% exceeded the ~~ORR was 44%. The disease control rate was 75%~~pre-specified lower bound of 20%. The median duration of response was ~~5.4~~5.7 months and ~~the~~ median progression free survival was 5.6 months. ~~88% of patients had dose interruptions and 77% had reductions from the 16mg QD starting dose, while 13% had AE related discontinuations.~~ The most common treatment related Grade ≥ 3 adverse events were ~~typical~~rash (30%), stomatitis (19%), diarrhea (14%), and paronychia (7%). In addition, the incidence of ~~TKIs and what we’ve seen in prior studies.~~ Grade ~~3 AEs were rash, stomatitis, diarrhea, and paronychia. Importantly, Grade~~≥ 3 pneumonitis was ~~only seen in one patient. In general, the~~low at 3%. The safety profile was ~~manageable. Following these first 48~~consistent with the TKI class.

On September 22, 2022, the Company met with ODAC to review poziotinib for the treatment of patients ~~we are now dosing patients at~~with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the ~~8mg BID dosing schedule.~~

~~Table~~current benefits of ~~Contents~~

~~Anti-CD20-IFNα:~~

In April 2019, we executed a license agreement with ImmunGene for an antibody-interferon fusion molecule directed against CD20 (Anti-CD20-IFNα) that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma (“NHL”),poziotinib did not outweigh its risks. ~~This technology~~ODAC is ~~designed~~an independent panel of experts that reviews and evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer. ODAC makes appropriate recommendations to ~~selectively target NHL with therapeutic doses of IFNa, while minimizing systemic toxicity. Under~~ the ~~terms of this agreement, we received~~FDA, but these recommendations are not binding and the ~~exclusive worldwide rights to commercialize this drug for any indication, and are financially responsible for~~final decision regarding product approval will be made solely by the ~~clinical and regulatory development programs.~~FDA.

Components of Operating Results

See Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Components of Operating Results of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, for a discussion of the nature of our revenue and operating expense line items within our accompanying Condensed Consolidated Statements of Operations.

Critical Accounting Policies and Estimates

See Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, for a discussion of significant estimates and assumptions made by our management as part of the preparation of our accompanying Condensed Consolidated Financial Statements. These critical accounting policies and estimates arise in conjunction with the following accounts in the preparation of this Form 10-Q:

•~~Revenue recognition;~~

•~~Property and equipment, net;~~

•Stock-based compensation; and

•Research and development costs.

Results of Operations

Table of Contents

Comparison of the Three and Nine Months Ended September 30, ~~2021~~2022 and ~~2020~~2021

Three Months Ended
September 30, Change Nine Months Ended
September 30, Change
2021 2020 $ % 2021 2020 $ %
(in thousands) (in thousands) ($ in thousands) (in thousands)
Operating costs and expenses:
Selling, general and administrative $ 12,243 $ 15,116 $ (2,873) (19.0) % $ 41,515 $ 44,654 $ (3,139) (7.0) %
Research and development 20,850 24,453 (3,603) (14.7) 69,335 62,192 7,143 11.5
Total operating costs and expenses 33,093 39,569 (6,476) (16.4) 110,850 106,846 4,004 3.7
Loss from continuing operations before other income (expense) and income taxes (33,093) (39,569) 6,476 (16.4) (110,850) (106,846) (4,004) 3.7
Interest income, net 11 188 (177) (94.1) 121 1,217 (1,096) (90.1)
Other income (expense), net 9 (9,131) 9,140 (100.1) (7,948) (15,720) 7,772 (49.4)
Total other income (expense) 20 (8,943) 8,963 (100.2) (7,827) (14,503) 6,676 (46.0)
Loss from continuing operations before income taxes (33,073) (48,512) 15,439 (31.8) (118,677) (121,349) 2,672 (2.2)
Provision for income taxes from continuing operations — (6) 6 (100.0) (9) (15) 6 (40.0)
Loss from continuing operations (33,073) (48,518) 15,445 (31.8) (118,686) (121,364) 2,678 (2.2)
Income (loss) from discontinued operations, net of income taxes (11) 66 (77) (116.7) (227) 255 (482) (189.0)
Net loss $ (33,084) $ (48,452) $ 15,368 (31.7) % $ (118,913) $ (121,109) $ 2,196 (1.8) %

~~Table of~~ ~~Contents~~


	Three Months Ended September 30,				Change				Nine Months Ended September 30,				Change
	2022		2021		$		%		2022		2021		$		%
	(in thousands)				(in thousands)				($ in thousands)				(in thousands)

Operating costs and expenses:

Selling, general and administrative	$	8,263	$	12,243	$	(3,980)	(32.5)	%	$	27,518	$	41,515	$	(13,997)	(33.7)	%
Research and development	13,335		20,850		(7,515)		(36.0)	%	33,535		69,335		(35,800)		(51.6)	%

Total operating costs and expenses	21,598		33,093		(11,495)		(34.7)	%	61,053		110,850		(49,797)		(44.9)	%
Loss from continuing operations before other income (expense) and income taxes	(21,598)		(33,093)		11,495		(34.7)	%	(61,053)		(110,850)		49,797		(44.9)	%
Interest income, net	128		11		117		1063.6	%	256		121		135		111.6	%
Other income (expense), net	(443)		9		(452)		(5022.2)	%	(5,534)		(7,948)		2,414		(30.4)	%
Total other income (expense)	(315)		20		(335)		(1675.0)	%	(5,278)		(7,827)		2,549		(32.6)	%
Loss from continuing operations before income taxes	(21,913)		(33,073)		11,160		(33.7)	%	(66,331)		(118,677)		52,346		(44.1)	%
Provision for income taxes from continuing operations	(16)		—		(16)		—	%	(45)		(9)		(36)		400	%
Loss from continuing operations	$	(21,929)	$	(33,073)	$	11,144	(33.7)	%	$	(66,376)	$	(118,686)	$	52,310	(44.1)	%
Income (loss) from discontinued operations, net of income taxes	4		(11)		15		(136.4)	%	(39)		(227)		188		(82.8)	%
Net loss	$	(21,925)	$	(33,084)	$	11,159	(33.7)	%	$	(66,415)	$	(118,913)	$	52,498	(44.1)	%

Quarterly Discussion

Selling, General and Administrative. Selling, general and administrative ~~expense~~expenses decreased by ~~$2.9~~$4.0 million in the current ~~year period,~~period. This decrease primarily relates to (i) a $1.7 million decrease in personnel expenses primarily related to the reduction in workforce during the strategic restructuring that began in January 2022, (ii) a decrease in stock-based compensation expense of $1.5 million, and (iii) a decrease of $0.8 million ~~of decreased IT infrastructure and system expenses and $1.6 million of decreased professional and outside service expenses as a result of a reduction~~ in ~~audit and consultancy fees.~~other general expenses.

Research and Development. Research and development expenses decreased by ~~$3.6~~$7.5 million in the current period, primarily due to decreased program activities of ~~$6.3~~$2.7 million for ~~Rolontis, partially offset~~ROLVEDON, $0.9 million for poziotinib, and $0.9 million related to our early-stage compounds. Personnel expenses decreased by ~~$2.2~~$3.0 million ~~of increased Poziotinib process development and testing expenses and $0.6 million of increased personnel-related expenses.~~related to the reduction in workforce during the strategic restructuring that began in January 2022.

Total Other Income (Expense). Total other ~~income (expense)~~expense increased by ~~$9.0~~$0.3 million primarily due to ~~$9.0~~a decrease of $2.9 million of ~~unrealized~~realized gains recorded ~~from~~during the current period for the sale of our equity holdings, partially offset by a $2.6 million increase in the market value of our equity holdings compared to the prior year period.

Year to Date Discussion

Selling, General and Administrative. Selling, general and administrative expenses decreased ~~$3.1~~by $14.0 million in the current year ~~period,~~period. This decrease primarily relates to (i) a $3.5 million decrease in personnel expenses, primarily related to ~~$2.8 million of decreased professional and outside service expenses as a result of a~~the reduction in ~~audit and consultancy fees and $0.3~~workforce during the strategic restructuring that began in January 2022, (ii) a decrease in stock-based compensation expense of $4.1 million, (iii) a decrease in deferred compensation expense of ~~decreased personnel related expense~~$3.1 million given decreases in the overall market compared to the prior ~~period.~~year period, (iv) a decrease of $1.4 million in professional services, (v) a decrease in marketing spend of $1.0 million, and (vi) a decrease of $0.7 million in other general expenses.

Research and Development. Research and development expenses ~~increased~~decreased by ~~$7.1~~$35.8 million in the current period, primarily due to ~~(i) increased~~the reversal of an $11.2 million ROLVEDON drug substance accrual during the period. A concession was provided by Hanmi for drug substance which had been accrued during 2021 and is no longer payable. Expenses also decreased in the current period due to decreased program activities of ~~$9.0~~$12.4 million for ROLVEDON, $4.9 million for poziotinib, and ~~(ii) $3.7~~$2.1 million ~~of increased personnel-related expenses. These increases were partially offset by (i) $4.7 million of decreased program activities for Rolontis, and (ii) $1.6 million of decreased spend~~ related to our ~~early stage~~early-stage compounds. Personnel expenses decreased by $5.2 million related to the reduction in workforce during the strategic restructuring that began in January 2022.

Total Other ~~Expense.~~Income (Expense). Total other expense decreased by ~~$6.7~~$2.5 million ~~in the current year period~~ primarily due to ~~an increase~~a $9.5 million reduction of ~~(i) $3.2 million~~unrealized losses in ~~the market value of~~ our equity holdings ~~(ii) $3.9~~ compared to the prior year period. This decrease was partially offset by a $5.7

Table of Contents

million ofincrease in realized ~~gains from~~losses recorded during the current period for the sale of our equity holdings ~~(iii) $0.2~~in addition to a $1.3 million ~~of gains from~~loss on our life insurance policies, and (iv) $0.5 million of lower currency exchange losses, compared to the prior year period. These gains were partially offset by $1.1 million of lower interest income from our investments.deferred compensation plan assets.

Liquidity and Capital Resources

WeThe Company expects to incur future net losses as it continues to fund the advancement and commercialization of its product candidates. Based upon our current projections, including our intention to continue to place a disciplined focus on streamlining our business operations, we believe that our ~~$133.6~~$100.3 million in aggregate cash, cash equivalents and marketable securities as of September 30, ~~2021,~~2022, will be sufficient to fund our current and planned operations for at least the next twelve months. WeHowever, should our costs and expenses prove to be greater than we currently anticipate, or should we change our current business plan in a manner that increases or accelerates our anticipated costs and expenses, we may ~~however,~~ require additional liquidity ~~as we continue to execute our business strategy, and in connection with opportunistic acquisitions or licensing arrangements. We anticipate that to~~earlier than expected. To the extent ~~that~~it becomes necessary to raise additional cash in the future, we ~~require additional liquidity,~~will seek to raise it ~~will be funded~~ through ~~additional~~the public or private sale of debt or equity securities, out-licensing arrangements, funding from joint-venture or strategic partners, debt ~~financings,~~financing or ~~out-licensing arrangements.~~short-term loans, or through a combination of the foregoing. However, we do not currently have any binding commitments for additional financing. Accordingly, we cannot provide any assurance that we will be able to obtain ~~this~~ additional liquidity on terms favorable to us or our current stockholders, ifor at all. ~~Additionally, our~~Our liquidity and our ability to fund our capital requirements going forward are ~~also~~ dependent, in part, on ~~our future financial performance which is subject to various~~ market and economic factors that are beyond our control. The Company may never achieve profitability or generate positive cash flows, and unless and until it does, the Company will continue to need to raise additional capital.

~~Net~~ On September 21, 2022, we entered into a Loan and Security Agreement (“Loan Agreement”), by and among the Company, Allos Therapeutics, Inc., Talon Therapeutics, Inc., and Spectrum Pharmaceuticals International Holdings, LLC, as borrowers, SLR Investment Corp. as administrative agent and the lenders party thereto that provides for a five-year senior secured term loan facility in an aggregate principal amount of up to $65.0 million available to us in four tranches (collectively, the “Term Loans”). As of September 30, 2022, we have drawn a total of $30.0 million of the Term Loans pursuant to the Loan Agreement, with a remaining undrawn principal balance of $35.0 million, which is available through December 31, 2023 and is subject to the achievement of certain milestone events. Refer to Note 5 of our accompanying Condensed Consolidated Financial Statements for additional information.

Cash ~~Used In~~ Flows

The following table summarizes our sources and uses of cash for each of the periods presented:


	Nine Months Ended September 30,
(in thousands)	2022		2021
Net cash used in operating activities	$	(71,651)	$	(89,139)
Net cash (used in) provided by investing activities	(36,241)		97,469
Net cash provided by financing activities	75,669		53,100
Effect of exchange rate on cash and cash equivalents	(61)		(4)
Net (decrease) increase in cash and cash equivalents	$	(32,284)	$	61,426

Operating Activities

~~Net~~During the nine months ended September 30, 2022, we used $71.7 million of cash ~~used~~ in operating activities, resulting from our net loss of $66.4 million and the change in operating assets and liabilities of $18.2 million, offset by non-cash charges of $12.9 million. Our non-cash charges were comprised of stock-based compensation expense of $7.6 million, unrealized loss on equity holdings of $3.4 million, realized loss on the sale of equity holdings of $1.1 million, non-cash lease expense of $0.5 million, depreciation and amortization of $0.2 million, and other non-cash items of $0.1 million. The change in our operating assets and liabilities was ~~$89.1 million for~~primarily related to a decrease in our accounts payable and accrued liabilities and our purchase of inventory.

During the nine months ended September 30, 2021, ~~as compared to $88.3~~we used $89.1 million ~~in the prior year period. This increase in net~~of cash ~~used~~ in operating activities, ~~was primarily related to increased research~~resulting from our net loss of $118.9 million, offset by changes in operating assets and ~~development program spend.~~

~~Net Cash Provided~~liabilities of $4.2 million and non-cash charges of $25.6 million. Our non-cash charges were comprised of stock-based compensation expense of $12.7 million, unrealized loss on equity holdings of $12.8 million, loss on disposal of manufacturing equipment of $3.1 million, non-cash lease expense of $1.2 million, depreciation and amortization of $0.2 million, and other non-cash items of $0.3 million offset by ~~Investing Activities~~

Net cash provided by investing activities was $97.5 million for the nine months ended September 30, 2021, as compared to $16.2 million during the prior year period. The cash provided by investing activities for the first nine months of 2021 primarily relates to $109.8 million of proceeds from maturities of our investments and $4.4 million of proceeds received fromrealized gains on the sale of ~~our equity holdings. This cash received was partially offset by $16.6 million of purchased investments and $0.1 million of purchased property and equipment.~~

~~Net Cash Provided by Financing Activities~~

Table of Contents

~~Net~~equity holdings of $4.6 million. The change in our operating assets and liabilities was primarily related to an increase in our accounts payable and accrued liabilities.

Investing Activities

During the nine months ended September 30, 2022, net cash used in investing activities was $36.2 million and consisted primarily of purchases of investments of $41 million, which was offset by proceeds from maturities and investments of $2.8 million and from the sale of equity holdings of $2 million.

During the nine months ended September 30, 2021, net cash provided by investing activities was $97.5 million and consisted primarily of proceeds from maturities of investments of $109.8 million and $4.4 million from the sale of equity holdings offset by $16.6 million of purchases of investments.

Financing Activities

During the nine months ended September 30, 2022, net cash provided by financing activities was $75.7 million consisting of proceeds from the issuance of debt, net of debt issuance costs of $28.9 million, $26.6 million from the sale of common stock under an at-the-market sales agreement, net, $20 million from the issuance of common shares to Hanmi and $0.3 million from the sale of stock under our employee stock purchase plan.

During the nine months ended September 30, 2021, net cash provided by financing activities was $53.1 million ~~for the nine months ended September 30, 2021, as compared to $84.9 million during the prior year period. Our cash provided by financing activities for the first nine months of 2021~~ primarily ~~relates to~~consisting $52.6 million of proceeds from ~~shares~~the sale of common stock ~~sold pursuant to~~under an at-the-market sales agreement, net, and $0.5 million from the sale of ~~proceeds from employee~~ stock ~~purchases~~ under our employee stock purchase plan.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements during the periods presented, nor do we currently have any, as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, ~~2021.~~2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. These include controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Based on the evaluation of our disclosure controls and procedures as of September 30, ~~2021,~~2022, our chief executive officer and chief financial officer concluded that, as of that date, our disclosure controls and procedures were effective.

Changes in Internal Controls Over Financial Reporting

There has been no change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the third fiscal quarter of ~~2021~~2022 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

Limitations on Ensuring the Effectiveness of Internal Controls

Table of Contents

An internal control system, no matter how well conceived and operated, cannot provide more than reasonable assurance that its objectives are completely met due to inherent limitations. Accordingly, no evaluation can provide absolute assurance that all internal control issues within a company have been detected. As part of our ongoing activities, we continuously seek to improve the efficiency and effectiveness of our business operations and accompanying internal controls.

Part II. Other Information

Item 1. Legal Proceedings

~~Table of~~ ~~Contents~~

particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.

Certain of the legal proceedings in which we are involved are discussed in Note 6(g), “Financial Commitments and Contingencies and Key License Agreements,” to our accompanying Condensed Consolidated Financial Statements, and are hereby incorporated by reference.

Item 1A. Risk Factors

~~Except as set forth below, as~~As of the date of this filing, except as discussed below, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, as filed with the SEC on March ~~31, 2021, and our Quarterly Report on Form 10-Q for the period ended June 30, 2021, as filed with the SEC on August 12, 2021.~~17, 2022.

~~Our supply of APIs and drug products is and will remain~~We are highly dependent upon Hanmi, as the sole supplier for ROLVEDON drug substance.

In February 2018, we entered into a non-exclusive supply agreement with Hanmi which was amended and restated in December 2019 and further amended and restated in January 2022, through which Hanmi manufactures and supplies drug substance for ROLVEDON.

Hanmi manufactures the ROLVEDON drug substance at its facility in Korea. As Hanmi is our only approved ROLVEDON drug substance manufacturer and the production ~~capabilities~~ of ~~CMOs~~all of our ROLVEDON drug substance is at a single location, we are exposed to the risk that Hanmi’s facility may be harmed or rendered inoperable by natural or man-made disasters or pandemics, which could render it difficult or impossible for Hanmi to perform its manufacturing activities for some time. At this time there are no plans to establish a redundant manufacturing facility to reduce this risk. If there is a supply deficiency, Hanmi will notify us of the deficiency and, ~~other third-parties for~~in such circumstances, we are required under the supply agreement to work with Hanmi to cure its supply failure. Furthermore, if Hanmi fails to comply with applicable regulatory requirements and maintain the FDA clearances related ~~supplies and logistical services. Some~~to the manufacturing of ~~these vendors are based overseas. If our CMOs and other suppliers are not able to meet our requirements or FDA scrutiny,~~the drug substance, we may be unable to ~~obtain approval for our products. Even if~~maintain commercial supply of ROLVEDON on a timely basis, or at all.

If Hanmi is unable to supply the drug substance to manufacture ROLVEDON reliably and at the levels we ~~do obtain approval for our products,~~anticipate or that are required by the market, we may be ~~limited in our ability~~unable to meet demand for our products, ensure regulatory compliance, or maximize profit on the future sale of our products. Any manufacturing-related disruptions could create significant demand on our limited capital resources, and there can be no assurance that we would be able to continue asapprove a ~~going concern.~~

~~In addition, our dependence on these ex-U.S. vendors also subjects us to business interruption risks related to COVID-19, and/or similar outbreaks, which could have a material adverse impact on us.~~

~~We have no internal manufacturing capacity for APIs or our~~substitute drug products. We therefore have entered into agreements with CMOs and other suppliers to supply us with APIs and our finished drug products. Success in the development and marketing of our drug products depends, in part, upon our ability to maintain, expand and enhance these existing relationships and establish new sources of supply. The manufacture of APIs and finished drug products, including the acquisition of compounds used in the manufacture of the finished drug products, may require considerable lead times. We have little or no control over the production processes of third-party manufacturers, CMOs or other suppliers. Some of the third-party manufacturing facilities used in the production of APIs and our drug products are located outside of the U.S. and require FDA approval, which they may have limited experience with obtaining. Our CMOs and other suppliers are subject to inspection by the FDA and may receive observations that they may not be able to resolve in a timely or effective manner, which could impact whether our products can be approvedsubstance manufacturer on a timely basis, if at all. We recently received a Complete Response Letter from the FDA for our Rolontis BLA that cited various manufacturing deficiencies at our API and our fill-and-finish suppliers. There is no guarantee that the remediation efforts will be found to be acceptable by the FDA.

The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of manufacturing and testing techniques, process controls, and scaling of production to meet commercial requirements. Manufacturers of pharmaceutical products often encounter difficulties during preparation for production, including technical challenges production costs, yields, quality control and assurance. If manufacturing deficiencies are noted by the FDA at any of the manufacturing facilities utilized in our products, there can be no assurance that we, or our CMOs, can resolve these manufacturing deficiencies on a timely basis, if at all. Any manufacturing-related disruptions could create significant demand on our limited capital resources, and there can be no assurance that we would be able to continue as a going concern.

Our ability to source APIs and drug products is also dependent on providers of logistical services who may be subject to disruptions that we cannot predict or sufficiently plan around. Accordingly, while we do not currently anticipate shortages of supply, circumstances could arisesell ROLVEDON commercially depends, in which we will not have adequate supplies to timely meet our requirements or market demand for a particular drug product could outstrip the ability of our supply source to timely manufacture and deliver the product, thereby causing us to lose sales. In addition, our ability to make a profit on the sale of our drug products dependspart, on our ability to obtain ~~favorable pricing~~such drug substance in accordance with regulatory requirements and in sufficient quantities for ~~these arrangements.~~

commercial supply. As such, we are highly dependent upon Hanmi’s continued ability to supply drug substance at the levels we require. If ~~problems arise during~~Hanmi is unable to supply ROLVEDON drug substance at the manufacture of a batch of our drug products, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause of the problem and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. To the extent that one of our suppliers experiences significant manufacturing problems,levels we require, this could have a material adverse effect on our ~~revenues~~business, financial condition and ~~profitability.~~results of operations and adversely affect our ability to satisfy demand for ROLVEDON, which could have adversely affect our product sales and operating results materially.

We have not been in compliance with the requirements of the NASDAQ Stock Market for continued listing and if NASDAQ does not concur that we have adequately remedied our non-compliance, our common stock may be delisted from trading on NASDAQ, which could have a material adverse effect on us and our shareholders.

The Company received notice pursuant to a letter dated November 1, 2022 from The NASDAQ Stock Market (“Nasdaq”) that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive

Table of Contents

business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market.

~~Reliance~~Nasdaq's notice has no immediate effect on ~~CMOs entails risks~~the listing of the Company's common stock on the Nasdaq Global Market. Pursuant to ~~which we~~Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 1, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to May 1, 2023.

If the Company does not regain compliance by May 1, 2023, the Company may be eligible for an additional grace period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Nasdaq staff determines that the Company will not be ~~subject~~able to cure the deficiency, or if ~~we manufactured products ourselves, including reliance on~~ the ~~third party~~Company is otherwise not eligible for ~~regulatory~~such additional compliance ~~and adherence to~~period, Nasdaq will provide notice that the FDA’s current Good Manufacturing Practice (“cGMP”) requirements, the possible breach of the manufacturing agreement by the CMO and the possibility of termination or non-renewal of the agreement by the CMO, based on its own business priorities, at a time that is costly or inconvenient for us. Before we can obtain marketing approval for our drug products, our CMO facilities must be approved by the FDA and typically pass a pre-approval inspection. In order to obtain FDA approval, the FDA must conclude that all of the suppliers’ manufacturing methods, equipment and processes comply with cGMP requirements.

The cGMP requirements govern organization and personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling control, holding and distribution, laboratory controls, records and reports, and returned and salvaged drug products. In addition, our CMOsCompany's common stock will be subject to ~~on-going periodic inspection by~~delisting. The Company would have the FDA and corresponding state and foreign agencies for compliance with their cGMP requirements, regulations and other regulatory standards. We do not have control over our CMOs’ compliance with these regulations and standards. Any failure of our third party manufacturers or usright to comply with applicable regulations, including an FDA pre-approval inspection, periodic on-going inspection by the FDA and cGMP requirements, could result in sanctions being imposed on them or us, including warning letters, fines, injunctions, civil penalties, failure of regulatory authoritiesappeal a determination to grant marketing approval of our products, delay, suspension or withdrawal of approvals, license revocation, seizures or recalls of product, operation restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.

Finally, our business could be adversely impacted by the effects of the COVID-19 pandemic, or by other public health emergencies. We source some of our APIs and other materials from Asia, including China and South Korea. Due to our current reliance on these vendors for ROLONTIS and poziotinib supply, we risk disruption in our supply chain (including restrictions on export or shipment), depending on the severity of the coronavirus outbreak and the potential government restrictions placed on our vendors or their transports.

If our suppliers fail to deliver materials and services needed for commercial manufacturing in a timely and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of ourdelist its common stock, and ~~other securities could decline.~~

~~We must rely~~the common stock would remain listed on ~~all of our suppliers to comply with relevant regulatory and other legal requirements, including~~ the ~~production of API in accordance with~~Nasdaq Global Market until the FDA’s cGMP for drug products. Although we conduct our own inspections and review and/or approve investigations of each supplier, there can be no assurance that the FDA, upon inspection, would find that the supplier is complying with the cGMP requirements, where applicable. If a supplier fails to comply with these requirements or the comparable requirements in foreign countries, regulatory authorities may subject them or us to regulatory action, including criminal prosecutions, fines and suspensioncompletion of the manufacture of our products. If we are required to find a new or additional supplier, we will need to evaluate that supplier’s ability to provide material that meets regulatory requirements, including cGMP requirements, as well as our specifications and quality requirements, which would require significant time and expense and could delay the production of our drug products. In general, if any of our suppliers is unwilling or unable to meet its supply obligations or if we encounter delays or difficulties in our relationships with manufacturers or suppliers, and we are unable to secure an alternative supply source in a timely manner and on favorable terms, our business, financial condition, and results of operations may be harmed and the market price of our common stock may decline.

The ongoing COVID-19 pandemic and the future outbreak of other highly infectious or contagious diseases, could materially and adversely impact or disrupt our business and our financial condition, results of operations, cash flows and performance.

The global health crisis caused by the COVID-19 pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts, remains uncertain and cannot be predicted with confidence. In addition, a new Delta variant of COVID-19, which appears to be the most transmissible variant to date, has begun to spread globally. The impact of the Delta variant cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19 vaccines against the Delta variant, and the response by governmental bodies and regulators. The ongoing COVID-19 pandemic has impacted our business and will likely continue to impact our business directly and/or indirectly for the foreseeable future.

We have maintained our operations during the COVID-19 pandemic by requiring most of our employees to work remotely. Only those employees performing essential activities that must be completed on-site are allowed in our facilities. These modifications to business activity may negatively impact productivity and cause disruptions and delays to our business. Longer term remote working environments could increase our cyber security risk, create data accessibility concerns, and make

~~Table of~~ ~~Contents~~

us more susceptible to communication disruptions. When we reopen our facilities, we could encounter delays in connection with implementing precautionary measures to mitigate the risk of exposing our employees to COVID-19.

Although the COVID-19 pandemic has not materially affected our clinical development programs to date, certain of our clinical programs have seen slower enrollment and there have also been delays in initiating new studies as a result of the COVID-19 pandemic. These delays are not seen across all our trials and are specific to certain trials enrolling at certain sites. In the future, the COVID-19 pandemic could further adversely affect our ability to enroll and recruit patients in current and future clinical trials, as well as delay data collection and analysis, any of which could cause a delay or denial of regulatory approval of our product candidates. Our success is dependent on our ability to advance our development programs into later stages of clinical development. Many pharmaceutical and biotechnology companies have indicated that their clinical trials will be delayed and enrollment of current and ongoing trials will suffer as a result of the COVID-19 pandemic. We anticipate the potential for delays in the initiation and enrollment of planned clinical trials until the pandemic resolves.

The COVID-19 pandemic, including the more contagious Delta variant of COVID-19, could also potentially affect the business of the FDA as well as other health regulatory authorities, which may have slower response times or be under-resourced and, as a result, review, inspection, and other timelines may be materially delayed. This could result in delays in our communications with these authorities and ultimately in the ability for us and our partners to have drug products approved. In 2020 and 2021, a number of companies announced receipt of Complete Response Letters due to COVID-19 related issues including the FDA’s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review or inspections resulting from such disruptions could materially affect the development and study of our drug candidates.

On October 26, 2020, we announced that the FDA had deferred action on the BLA for ROLONTIS due to its inability to conduct an inspection of the Hanmi manufacturing facility in South Korea as a result of travel restrictions associated with the COVID-19 pandemic. In early June 2021, the FDA conducted the pre-approval inspection of the Hanmi manufacturing facility. In August 2021, we received a Complete Response Letter from the FDA regarding our BLA, citing deficiencies related to manufacturing and indicating that a reinspection will be necessary. We are currently working on remediating the manufacturing deficiencies and expect that this work will be complete in the fourth quarter of 2021 and plan to resubmit thereafter. However, we cannot guarantee that we, together with our contract manufacturers, will be able to remediate the cited deficiencies in a timely manner, or at all, and we cannot predict whether the COVID-19 pandemic will again delay or even prevent the FDA from completing any reinspections that may be required in connection with a resubmission of the BLA for ROLONTIS.

The COVID-19 pandemic could also adversely affect our supply chain for other third party vendors for research supplies, development activities including manufacturing of drug product for our clinical studies and testing of drug material. If any of the vendors in our supply chain of products or services are severely affected from the COVID-19 pandemic, it will adversely affect our ability to continue our research and development activities and also continue our clinical trial activities. Disruptions to our business operations or operations of our third-party manufacturers and CROs on which we rely to conduct our clinical trials could be significant and of undetermined length. Significant restrictions or bans on travel could impede, delay, limit or prevent our employees and CROs from continuing research and development activities.

The COVID-19 pandemic, including the recent Delta variant, and mitigation measures have continued to adversely impact global economic conditions which could have an adverse effect on our business and financial condition, including impairment of our ability to raise capital when needed. The trading prices for biopharmaceutical companies’ stock have been highly volatile as a result of the COVID-19 pandemic. In addition, the continued spread of COVID-19 could cause a recession, depression, or other sustained adverse market event which could materially and adversely affect our business and the value of our common shares. In particular, it is unclear how our business may be affected by the emergence of new variants of COVID-19, such as the Delta variant, and recent resurgence in number and rates of COVID-19 infections. Furthermore, to the extent the ongoing COVID-19 pandemic adversely affects our operations and business, it may also heighten the other risks described in our Annual Report on Form 10-K for the year ended December 31, 2020, and other filings that we have made with the SEC.

appeal process.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 21, 2022, in connection with our entry into the Loan Agreement, we granted Warrants to the Lenders to purchase up to 454,454 shares of our common stock at an exercise price of $0.66 per share, which had a fair market value at the time of issuance of $0.2 million. The number of shares and exercise price are subject to anti-dilution adjustments for splits, dividends, capital reorganizations, reclassifications and similar transactions. The Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance.

~~None.~~The Warrants were issued in a private placement pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2) promulgated pursuant to the Securities Act. Each Lender represented that it is an accredited investor, and that it was acquiring the securities for its own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act.

The additional information regarding the Loan Agreement and the Warrants in Note 5, “Loan Payable” is hereby incorporated by reference.

Item 3. Defaults Upon Senior Securities

~~Table of~~ ~~Contents~~

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

None.

3735

Table of Contents

Item 6. Exhibits

Incorporated by Reference

Exhibit
Number

Description

Form

Form No.

Exhibit

Filing Date

Filed/Furnished Herewith

Exhibit
Number

Description

Form

Form No.

Exhibit

Filing Date

Filed Herewith

2.1

Asset Purchase Agreement, dated January 17, 2019, by and among Spectrum Pharmaceuticals, Inc., Acrotech Biopharma LLC and Aurobindo Pharma USA, Inc.

8-K

001-35006

10.1

1/17/2019

2.1

Asset Purchase Agreement, dated January 17, 2019, by and among Spectrum Pharmaceuticals, Inc., Acrotech Biopharma LLC and Aurobindo Pharma USA, Inc.

8-K

001-35006

10.1

1/17/2019

3.1

Restated Certificate of Incorporation.

8-K

001-35006

3.1

6/18/18

3.1

Restated Certificate of Incorporation.

8-K

001-35006

3.1

6/18/18

3.2

Third Amended and Restated Bylaws

8-K

001-35006

3.1

3/29/2018

3.2

Third Amended and Restated Bylaws

8-K

001-35006

3.1

3/29/2018

10.1

Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.

10.2

Form of Stock Option Award Agreement under the Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.

10.3

Form of Restricted Stock Unit Award Agreement under the Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.

31.1

Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934.

31.1

Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934.

31.2

Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934.

31.2

Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934.

32.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

32.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

32.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

32.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

101.INS

Inline XBRL Instance Document. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

101.INS

Inline XBRL Instance Document. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith).

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith).

3836

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		SPECTRUM PHARMACEUTICALS, INC.

Date:	November 10, ~~2021~~2022	By:	/s/ ~~Kurt A. Gustafson~~Nora E. Brennan
			~~Kurt A. Gustafson~~Nora E. Brennan
			Executive Vice President and Chief Financial Officer
			(Authorized Signatory and Principal Financial and Accounting Officer)

3937


	September 30, 2021 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	92,172	$	—	$	—	$	92,172
Equity securities	10,237		—		—		10,237
Government-related debt securities	10,023		—		—		10,023


Mutual funds	5,900		9		—		5,909
Key employee life insurance, cash surrender value(1)	—		4,287		—		4,287
	$	118,332	$	4,296	$	—	$	122,628
Liabilities:
Deferred executive compensation liability(2)	$	—	$	10,489	$	—	$	10,489
	$	—	$	10,489	$	—	$	10,489


	September 30, 2021		December 31, 2020

Other miscellaneous receivables	$	2,443	$	901
Income tax receivable - current portion	1,297		1,297
Interest receivable from marketable securities	123		196

Other receivables	$	3,863	$	2,394


	September 30, 2021		December 31, 2020
Prepaid expenses and deferred costs	$	2,370	$	1,996
Prepaid insurance	170		2,165
Prepaid expenses and other current assets	$	2,540	$	4,161


	September 30, 2021		December 31, 2020
Manufacturing equipment	$	—	$	3,245
Computer hardware and software	1,802		1,680
Laboratory equipment	5		5
Leasehold improvements	1,267		1,267
Office furniture	307		248
Property and equipment, at cost	3,381		6,445
(Less): Accumulated depreciation	(2,874)		(2,868)
Property and equipment, net	$	507	$	3,577


Operating Leases - future payments	September 30, 2021
2021 (remaining)	$	382
2022	1,301
2023	657
2024	669
2025	98
2026	73
Total future lease payments, undiscounted	$	3,180
(Less): Implied interest	(136)
Present value of operating lease payments	$	3,044